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CHAPTER 1. GENERAL INTRODUCTION 
Dissertation Organization 
This dissertation was compiled using the altemate fonnat. Included in this 
dissertation is a general introduction of the dissertation and introduction to the 
research problem, a review of the literature regarding virulence factors of 
streptococci, two manuscripts conceming S. suis, and a final chapter with general 
conclusions that summarizes the results of the research and discusses their 
contribution to the understanding of S. sa/s-induced disease. The two manuscripts 
will be submitted for publication. The references cited for each chapter are found 
immediately following that chapter. 
Statement of the Problem and Research Summary 
Streptococcus suis (S. suis) commonly colonizes the tonsils of healthy swine. 
However, S. suis infection may lead septicemia resulting in meningitis, arthritis, 
septicemia, and/or pneumonia.^® Medicated eariy weaning and other similar 
management practices have been unable to eliminate this disease. One of the 
reasons these practices are unable to control S. su/s-induced disease is that the 
tonsils of neonatal pigs can be colonized by S. suis through contact with the sow at 
birth or shortly thereafter.This disease remains a cause of morbidity and 
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mortality in herds that otherwise have a high health status.^ Currently available 
vaccines have limited ability to control the clinical syndrome.^® 
Phagocytes play a key role In defense against systemic bacterial infection 
and therefore should also be central in the defense against S. sa/s-induced disease. 
Outbreaks of S. sa/s-induced disease are often associated with the occurrence of 
stressors (such as weaning, mixing, vaccination, PRRSV Infection, or other 
Infectious agents) which may suppress phagocyte functions.'* It has been reported 
that pigs treated with Interleukin 1 had Increased activation of neutrophils and 
Increased resistance to S. suis challenge.These observations indicate that 
neutrophils play a key role In controlling S. suis Infection. 
In order to overcome the phagocytic defense system, a pathogen must have 
virulence factors to enable It to evade Ingestion and/or killing by phagocytic cells.^^ 
Several potential virulence factors of S. suis have been identified. These Include 
capsule, sullysin (a hemolysin), hemagglutinin, muramldase released protein and 
extracellular factor.The capsule Is the only virulence factor that has 
been defined as critical, the other factors do not consistently con-elate with virulence 
and are not essential for virulence.® ® There Is some congelation with capsular 
thickness and resistance to phagocytic killing; however, there Is a report of an isolate 
that did not have a thick capsule but was resistant to phagocytic killing.This 
suggests that there are other as yet undescribed virulence factors associated with S. 
suis that interfere with phagocyte function. 
Investigation of S. suis virulence and evaluation of S. suis vaccines requires a 
challenge model which mimics the natural route of Infection and reproduces the 
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disease syndrome. There are apparently no publications describing S. suis 
challenge models that meet this criteria. The published challenge models are 
intravenous inoculation of pigs, intranasal inoculation of pigs infected with other 
pathogens, or intravenous inoculation of mice as a model for pigs.^-®-^^-^® Although 
these models have contributed much to the understanding of S. suis disease, they 
also limit and confound some of the information needed to better understand S. suis 
disease in swine. In addition, it has recently been reported that the mouse is 
probably not a good model for evaluating virulence factors for S. suis.^^ 
The objectives of the research presented in this dissertation were to develop 
a challenge model that would mimic the natural route of exposure in pigs without the 
confounding factor of other infectious agents and to better understand S. suis 
interaction with neutrophils. The first manuscript describes a challenge model that 
fulfilled our objectives for a reproducible model that mimicked the clinical disease 
observed in the field. This model has been used in two subsequent studies that 
resulted in papers submitted for publication. The second manuscript describes a 
factor that is found in the supernatant of S. suis incubated in saline for two hours that 
decreases pig neutrophil function. The results are summarized and discussed in the 
general conclusions. 
References 
1. Amass SF. S. suis and SEW: the one that got away. Swine Consultant. Pfizer 
1996;Winter:4-9. 
4 
2. Amass SF, Clark LK, Knox K, et ai. Streptococcus suis colonization of piglets 
during parturition. Swine Health and Production 1996:4:269-272. 
3. Beaudoin M, Higgins R, Harel J, et al. Studies on a murine model for evaluation of 
virulence of Strepococcus suis capsular type 2 isolates. FEMS MicrobioLLett. 
1992:99:111-116. 
4. Chanter N, Jones PW, Alexander TJL. Meningitis in pigs caused by Streptococcus 
suis - a speculative review. Vet Microbiol. 1993:36:39-55. 
5. Chariand N, Harel J, Kobisch M, et al. Streptococcus suis serotype 2 mutants 
deficient in capsular expression, li^ icrobiol. 1998:144:325-332. 
6. Galina L, Pijoan C, Sitjar M, et al. Interaction between Streptococcus suis 
serotype 2 and porcine reproductive and respiratory syndrome virus in specific 
pathogen-free piglets. VetRec. 1994:134:60-64. 
7. Gottschalk M. Higgins R, Jacques M, et al. Production and characterization of two 
Streptococcus suis capsular type 2 mutants. VetMicrobiol. 1992:30:59-71. 
8. Gottschalk M, Lebrun A, Jacques M, et al. Hemagglutination Properties of 
Streptococcus suis. J.CIin.Microbiol. 1990:28:2156-2158. 
9. Gottschalk M, Lebrun A, Wisselink H, et al. Production of virulence-related 
proteins by Canadian strains of Streptococcus suis capsular type 2. Can. J. Vet.Res. 
1998:62:75-79. 
10. Gottschalk MG, Lacouture S, Dubreuil JD. Characterization of Streptococcus 
su/s capsular type 2 haemolysin. Microbiol. 1995:141:189-195. 
11. Iglesias JG, Trujano M, Xu J. Inoculation of pigs with Streptococcus suis type 2 
alone or in combination with pseudorabies virus. Am.J.Vet.Res. 1992:53:364-367. 
12. Jacobs AAC, Loeffen PLW, Van Den Berg AJG, etal. Identification, purification 
and characterization of a thiol-activated hemolysin (suilysin) of Streptococcus suis. 
Infectlmmun. 1994:62:1742-1748. 
13. Quessy S, Dubreuil DJ, Jacques M, et al. Increase of capsular material thickness 
following in vivo growth of virulent Streptococcus suis serotype 2 strains. FEMS 
MicrobioLLett. 1994:115:19-26. 
5 
14. Robertson ID, Blackmore DK. A longtidudinai study of natural infection of piglets 
with Streptococcus su/s types 1 and 2. EpidemioUnfect. 1991 ;107:119-126. 
15. Sanford SE, Higgins R. Streptococcal Diseases. In: Leman AD, Straw BE, 
Mengeling WL, D'Allaire S, Taylor DJ, eds. Diseases of Swine. 7 Ed. Ames, lA: ISU 
Press, 1992:588-589. 
16. Sanford SE, Schultz R, Straw B. Streptococcus suis disease in pigs. PIH 
1989:PIH:118 
17. Shi J, Goodband RD, Chengappa MM, et al. Influence of interleukin-1 on 
neutrophil function and resistance on Streptococcus suis in neonatal pigs. 
J.Leukoc.BioI. 1994:56:83-94. 
18. Vecht U, Arends JP, Van der Molen EJ, et al. Differences In virulence between 
two strains of Streptococcus suis type 2 after experimentally induced infection of 
newbom germfi-ee pigs. AmJ.VetRes. 1989:50:1037-1043. 
19. Vecht U, Stockhofe-Zunwieden N, Tetenburg BJ, et al. Virulence of 
Streptococcus suis type 2 for mice and pigs appeared host-specific. Vet Microbiol. 
1997:58:53-60. 
20. Vecht U, Wisselink HJ, Jellema ML, et al. Identification of two proteins 
associated with virulence of Streptococcus suis type 2. Infectlmmun. 
1991:59:3156-3162. 
21. Vecht U, Wisselink HJ, van Dijk JE, et al. Virulence of Streptococcus suis type 2 
strains In newbom gennfree pigs depends on phenotype. J.CIin.Micmbiol. 
1991:29:2590-2594. 
22. Wibawan IWT, Lammler C. Relation between encapsulation and various 
properties of Sfrepfococcus sw/s. J.Vet.Med. 1994:41:453-459. 
23. Zierler MK, Galan JR. Paradigms in bacterial entry Into host cells. In: Roth JA, 
Bolin CA, Brogden KA, Minion FC, Wannemuehler MJ, eds. Virulence Mechanisms 
of Bacterial Pathogens. 2nd Ed. Washington, DC: ASM Press, 1995:21-31. 
6 
CHAPTER 2. LITERATURE REVIEW: VIRULENCE FACTORS OF 
STREPTOCOCCI 
General Introduction 
Streptococci were first described in tlie 1800s as chaining cocci. Some 
common features of streptococci are that they are gram positive, grow in chains or 
pairs, and are facultative anaerobes. There are more than 40 types of streptococci 
as identified by a variety of grouping systems. The hemolysis pattem was one of the 
first ways used to categorize streptococci. Subsequently, in the 1930s, Rebecca 
Lancefield developed a new system for grouping streptococci. The Lancefield 
groupings are based on ceil wail carbohydrates (group specific antigens), e.g. 
teichoic acids. Lancefield groups include A through H and K through More 
recentiy the streptococci have been divided into groups based on differences in 16S 
rRNA and 16S rDNA. The major groups based on 16S rDNA are pyogenic, mitis, 
salivarius, bovis, anginosus, and mutans. However, one grouping system is not 
adequate for describing all members of the genus.^® For example, S. pyogenes Is a 
Lancefield group A streptococcus, and S. agalactiae is a Lancefield group B 
streptococcus, and in the 168 rDNA grouping system they are both in the pyogenic 
group. S. pneumoniae does not have a Lancefield grouping but is in the mitis group 
based on the 16S rDNA. S. suis is a Lancefield group D, however in the 16S rDNA 
system it remains ungrouped. 
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Streptococci are ubiquitous and can exist as commensals in their host or can 
cause fatal disease. Some streptococci are species specific and some cause 
disease in many different species. In general, the streptococci are very successful 
pathogens. They have many ways of surviving and evading the host immune 
system. Some mechanisms of evasion are unique to a certain type of streptococci, 
while other mechanisms are common to many types of streptococci and to many 
types of bacteria. 
One of the major mechanisms of defense against streptococci is the native 
immune system, including serum proteins and phagocytic cells. Many virulence 
factors of streptococci interact or influence phagocyte function. This chapter will 
review the virulence factors of some of the major streptococcal species that induce 
disease in humans and animals, and, where applicable, the important interactions 
with phagocytic cells. The major streptococci that will be discussed are Group A 
streptococci (GAS), Group B streptococci (GBS), S. pneumoniae and S. suis. 
Virulence Factors Associated with the Capsule of 
Streptococci 
The capsules of streptococci are made of various polysaccharides. In 
general, the capsules are large molecular weight molecules made of 2-8 different 
repeating units. Biosynthesis and transport of capsule in gram positives is pooriy 
understood.®^ The capsular components are assembled in the cytoplasm and 
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transported most likely via ATP-binding cassettes to the outside of the cell. They are 
attached to the bacterial cell by covalent linkages.® '^" 
Bacterial capsules can have many important functions. The capsule aides in 
survival by protecting the cell firom drying, since capsules are approximately 95% 
water.®^ In addition to preventing dehydration, the capsule contributes to 
transmission and adherence to host ceils. Some capsular molecules bind to host 
receptors and initiate the first step for successful infection. Another major 
contribution of the capsule to virulence in the host is evasion of host immune 
defenses. The capsule can be antiphagocytic because of its hydrophilicity and 
effects on complement activation and opsonization. The capsule is non-protein and 
often contains molecules that are not foreign to the host, e.g. hyaluronic acid and 
sialic acid, making It poorly immunogenic. Different species of streptococci have 
different features about their capsules that are important for the success of the 
pathogen in the host. 
Group A Streptococcus 
The capsule of GAS is composed of hyaluronic acid. The hyaluronic acid that 
is found in the bacterial capsule is identical to hyaluronic acid that is found in 
connective tissue of animals. The hyaluronic acid capsule is encoded by the has 
gene cluster. This gene cluster is found in all strains of GAS and seems to be 
invariant.^ '^^ ^ The importance of the capsule for virulence has been demonstrated 
using transposon-induced mutants. The LD50 in mice of unencapsulated mutants 
was 150 times that of the parent.^ '^^ '* The unencapsulated mutants had decreased 
ability to colonize oral/pharyngeal epithelium of mice and decreased ability to 
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establish an infection in skin and soft tissues. The hyaluronic acid capsule has two 
major contributions to virulence, evasion of the immune system and adherence to 
the host cells. It evades the immune response because it is not recognized as 
foreign, does not contain protein, and is poorly immunogenic. Encapsulated GAS 
are resistant to phagocytosis by neutrophils while unencapsulated mutants are 
readily phagocytosed.^ '^^ ^ The mechanism for the resistance is not completely 
understood. It was observed that unencapsulated isolates were susceptible to killing 
by polymorphonuclear cells (PMNs) in the presence of serum while the 
encapsulated isolates were more resistant. Therefore, it was thought that the 
capsule somehow interfered with opsonization by the complement system, making 
the encapsulated isolates resistant to phagocytosis. Further, experiments 
demonstrated that C3b bound equally to encapsulated and unencapsulated isolates. 
It was then proposed that the C3b bound to the capsule in a position in which it 
could not bind to the complement receptor on the phagocytic cell leading to 
resistance to phagocytosis.^ '^^ ^ 
The capsule of GAS is also important in adherence to host cells. CD44 is the 
hyaluronic acid receptor in the host and is found on epithelial cells, mesenchymal 
cells, and hematopoietic cells. The role of hyaluronic acid in adherence of the 
bacteria to epithelial cells was demonstrated using CD44 monoclonal antibodies. 
Antibody binding to CD44 caused a reduction of GAS binding to epithelial cells. In 
addition, transfection of CD44 negative cells with CD44 increased GAS binding to 
the CD44 transfected cells.®® It is interesting that CD44 is increased on host cells 
during inflammation, injury, and healing. These are conditions when GAS Infections 
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are often seen. The increase in CD44 receptors may contribute to increased GAS 
binding and infection. It is clear that the hyaluronic capsule of GAS is important in 
virulence. 
Group B Streptococcus 
There are 9 antigenic types of GBS capsules. The most common capsule 
types isolated from diseased hosts are types 11 and III. Like most bacterial capsules, 
the GBS capsules are high molecular weight polymers of repeating units of 4-7 
monosaccharides. The different GBS capsule types are composed of the same 
sugars, there are different antigenic types because these sugars are linked together 
differently. The different capsule types are correlated with disease in different aged 
hosts. For example, type III is almost always the serotype isolated from neonates 
and type II is the serotype isolated fi-om adults.^^ The reason for the different 
tropisms is unknown. 
The capsule is an essential virulence factor for GBS. This has been 
demonstrated with transposon-induced mutants and antibody protection studies.^ '* 
The LDso in rats of unencapsulated mutants was 100 times that of the wild type 
parent. All GBS capsules have side chains containing a terminal sialic acid. The 
terminal sialic acid negative mutants had an LD50 similar to the unencapsulated 
transposon mutant. '^^ '^^ ® This suggested that sialic acid was the Important 
component of the capsule that was contributing to virulence. Sialic acid probably 
contributes to virulence by its interaction with the alternative pathway of 
complement. Sialic acid increases the affinity of Factor H for C3b (either soluble or 
membrane bound). When Factor H binds to C3b then Factor I breaks down C3b.®® 
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Therefore, a bacterial capsule that contains sialic acid will have less complement 
activation by the altemative pathway and less C3b opsonization making it more 
resistant to phagocytosis. The opposite effect is also true, when sialic acid is 
removed from GBS capsule an increase in complement activation can be 
measured. 
S. pneumoniae 
The difference in virulence of encapsulated and unencapsulated S. 
pneumoniae was first demonstrated by Griffith in 1928.^® The encapsulated isolates 
were much more virulent that unencapsulated isolates. The S. pneumoniae capsule 
is composed of many types of sugars and ninety different antigenic types of capsule 
have been identified. 
The importance of the capsule type in virulence has been demonstrated by 
transformation studies. Transformation of S. pneumoniae cells with the capcity to 
encode for other capsule types has been demonstrated.^ In general, a strain can 
only synthesize one capsule type as determined by a specific genetic locus. 
However, there are regions of DNA homology in the S. pneumoniae genome 
representing different serotypes. During transformation homologous recombination 
promotes exchange between the donor DNA and the chromosome of the recipient, 
resulting in bacteria of the same serotype as the donor.^ This transforming 
capability of S. pneumoniae was used to demonstrate the role of capsule type in 
virulence. Three different isolates were used representing different capsular types 
and virulence characteristics in mice. The isolates were transformed with DNA 
encoding type 3 capsule and then the change in virulence examined. The change in 
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capsule type resulted in a change in virulence of the recipient. The virulence of the 
recipient was similar to that of the donor. The change in the virulence, however, 
could not be totally explained by the capsule type alone. It was therefore concluded 
that the capsule type contributes to vimlence but other factors also contribute.^^ The 
mechanism for one capsule type being more virulent than another capsule type 
remains unknown. 
S. suis 
The capsule of S. suis is composed of approximately 5 different sugars.®'^ ® 
Thirty-five serotypes have been identified based on the capsule and probably many 
more not yet identified. '^^  
It has been demonstrated that capsular thickness increases during in vivo 
growth and the thickness of capsule influences resistance to killing by phagocytes.®^ 
Experiments comparing phagocytosis of encapsulated and unencapsulated isolates 
demonstrated that the encapsulated bacteria are pooriy phagocytosed compared to 
unencapsulated. An unencapsulated transposon-induced mutant had an LD50 of 
greater than 100 times that of the parent bacteria when inoculated intravenously into 
a pig.® This result convincingly demonstrated the importance of the capsule in 
virulence, but the mechanism remains unclear. Sialic acid is one of the sugars 
found in the capsule of S. suis] however, it does not appear to be important in 
virulence.^" Virulent isolates of S. su/s treated with enzymes to remove sialic acid 
remained virulent. One explanation for the difference between this and GBS, where 
sialic acid is key to virulence, is that the concentration of sialic acid in the S. suis 
capsule is very low compared to Another explanation proposed is that 
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complement does not play an Important role in the phagocytosis of S. suis; 
therefore, sialic acid would not contribute to inhibition of phagocytosis.^" It has been 
demonstrated that virulent and aviruient isolates of S. suis are encapsulated and are 
equally phagocytosed. The difference between the two is that the virulent isolates 
survive longer in the phagocyte/ Therefore, certain capsule types may contribute 
to survival in phagocytes. More research is needed to identify the mechanism of the 
capsule in virulence. 
Virulence Factors Associated with the Cell Wall of 
Streptococci 
The cell walls of streptococci are made up of peptidoglycan and group 
specific polysaccharides (teichoic acids) and are the basis for the serologic group 
specific typing (Lancefield) for streptococci. The peptidoglycan is a polymer of p 1,4 
linked N-acetylglucosamine (NAG) and N-aceytlmuramic acid (NAM) with peptide 
side chains attached to NAM. The common peptide side chain Is L-alanine, D-
glutamic acid, L-lysine and D-alanine. The peptide side chains are then cross-linked 
by peptide bridges.®® The cross-linking of the peptides is what makes the 
peptidoglycan insoluble. The NAG-NAM is invariant between the streptococci, but 
the peptide side chains and cross-linking peptide bridges do vary between and 
within species. In addition to NAG-NAM and the linking peptides, the cell wall 
contains teichoic acids (or group specific polysaccharides) and lipoteichoic acids. 
Lipoteichoic acids are teichoic acids linked to the lipid portion of the cell membrane. 
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Typically, teichoic acids are composed of a sugar backbone, e.g., glycerol or ribitol 
and D-alanine. Assembly of the cell wall occurs by the transport of NAG-NAM 
disaccharide with its linked peptide side chain from the cytoplasm across the 
membrane to the surface. Once across the membrane it becomes part of the 
growing peptidoglycan chain.®^ 
A basic function of the cell wall is to allow the bacteria to maintain shape 
under a range of osmotic conditions. In addition, the cell wall generates many 
biological responses in the host. Some of the biological responses are complement 
activation, leukocyte chemotaxis, cytotoxicity of host cells, and induction of IL17° 
The contribution to virulence of these responses is not completely clear. It seems 
that some of the responses contribute to virulence while others are part of the 
protective response of the host. 
Group A Streptococcus 
The cell wall of GAS is composed of NAG-NAM and the usual peptide side 
chains. The interpeptide linkages in GAS are L-alanine oligopeptides.®® The Group 
A specific polysaccharide is composed of a repeating unit backbone of rhamnose 
and NAG. When the peptidoglycan and polysaccharide of GAS are purified and 
injected into a mouse the clinical signs of chronic Inflammation are observed.^^ The 
chronicity of the inflammation is thought to result from the persistance of the 
peptidoglycan and polysaccharide. Peptidoglycan and polysaccharide of GAS are 
not easily broken down by phagocytic cells or enzymes in the tissues and can 
persist in the host up to 40 days.®^ Fixation of complement, C5a recruitment and 
activation of PMNs cause inflammation. Another effect of the peptidoglycan and 
15 
polysaccharide is observed when neutrophils in serum are incubated with 
peptidoglycan and polysaccharide. The result is decreased ability of the neutrophils 
to phagocytose other bacteria. Addition of serum to the reaction mixture was 
required to observe the decreased phagocytic ability. One explanation given for this 
was that the peptidoglycan and polysaccharide activated the complement cascade 
and depleted the serum of complement components. The bacteria could not be 
opsonized and this resulted in decreased phagocytosis. Another explanation was 
that the peptidoglycan and polysaccharide bound the C3b and then competed with 
the opsonized bacteria for C3b receptors on the neutrophils resulting in decreased 
phagocytosis of the opsonized bacteria. The second explanation was the one 
thought to be most likely. The proposed mechanism of the GAS cell wall in virulence 
in vivo then is interference of the neutrophils ability to phagocytose bacteria.^ 
Group B Streptococcus 
The GBS cell wall is composed of NAG-NAM and a group specific antigen of 
•-glucosamine, D-galactose, D-glucitol, and D-rhamnose.^® The interpeptide bridge 
of GBS has L-serine in place ofsome of the L-alanines of GAS.®® There is little other 
information regarding GBS cell wall and its interactions with the host. 
S. pneumoniae 
The cell wall of S. pneumoniae has been studied extensively because of its 
contribution to the severe clinical disease observed during S. pneumoniae infections. 
S. pneumoniae cell wall is composed of peptidoglycan and teichoic acid. Many 
peptide subunits and cross-linkages have been described Teichoic acid of S. 
pneumoniae is unusual in that it contains choline in addition to more common 
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gaiactosamine and ribrtol. Purified cell wall of S. pneumoniae is able to induce 
inflannmation of the meninges in rabbits that is identical to that seen in 
pneumococcal meningitis.®® In contrast, the capsule induces little inflammation 
when it is purified and inoculated into a host. There is a long list of biological 
activities associated with the S. pneumoniae cell wall. The biological activities 
include: complement fixation, binding CD14, binding platelet activating factor 
receptor, induction of procoagulant activity on endothelial cells, activation of 
production of IL1, TNF, and IL12 from endothelium, epithelium, and leukocytes, 
chemotactic attraction of leukocytes, induction of NFkB, changes in the blood brain 
barrier pemneability, cytotoxicity for choroid plexus cells and neurons.^" 
The choline in S. pneumoniae teichoic acid binds to platelet activating factor 
(PAF) receptor. Binding of the pneumococci to these receptors is followed by 
invasion of the cell.^^ It is also interesting that the inflammatory response induced by 
the cell wall results in upregulation of PAF receptors on the cells.^^-^ Therefore the 
cell wall is considered a virulence factor in that it contributes to adherence of the 
bacteria. 
The choline In the cell wall is also Important for the activity of S. pneumoniae 
autolysin.'*® The autolysin will be discussed in the protein section of this chapter, but 
at a certain stage of growth the S. pneumoniae produce autolysin which cleaves the 
NAM-L-alanine bond of the cell wall. The autolysis of S. pneumoniae cells allows 
release of intracellular virulence factors. 
In summary, the cell wall of S. pneumoniae is important for survival of the 
bacteria, adhesion, and is responsible for many of the clinical signs seen in infected 
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individuals.®®'^ " Some of the responses obviously contribute to the bacteria's 
success while others seem not to be to the bacteria's advantage. 
S. suis 
The group D cell wall specific antigen of S. suis is glucosyl 
glycerophosphate.^^ This type of cell wall does not persist like the cell wall of GAS, 
and it does not induce the chronic inflammation seen with GAS.®^ There is no other 
infomnation available on the composition or contribution to virulence of the cell wall 
of S. suis. 
Protein Virulence Factors of Streptococci 
Bacterial proteins are manufactured in the cytoplasm and then either remain 
there or are exported. Most proteins that remain in the cytoplasm are involved in 
cellular metabolism and transportation of cellular products. Exported proteins 
include proteins that are associated with the cell surface or released to the 
extracellular space.^® Exported proteins vary widely in their functions and the 
functions of many remain unknown. 
The mechanisms for exporting bacterial proteins have been divided into three 
general types, type I or the ATP binding cassette (ABC) pathway, type II or the 
general secretory pathway (GSP), and type III or the contact secretion 
pathway.^® "'^  '*® All three types of secretion pathways use ATP as an energy source. 
Some of the proteins involved in transportation participate in more than one of the 
pathways. Both Gram positive and Gram negative bacteria use the GSP and ABC 
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pathways, but only Gram negative bacteria have been found to use the contact 
secretion pathway. 
The ABC pathway involves a complex of conserved proteins that transport the 
protein for export across the membrane. This process is not dependent on secretory 
proteins and results in transport of the whole protein across the membrane in one 
step.'*® 
The GSP pathway is currently thought to be the pathway most commonly 
used. This pathway is dependent on secretory proteins, recognition of a signal 
sequence and translocation to the cell membrane. The signal sequence is cleaved 
off of those proteins that are to be released extracellulariy and not cleaved off those 
proteins that are to remain anchored to the cell membrane. 
Type III, contact secretion, has many similarities with the ABC pathway. The 
differences are that the type ill pathway utilizes many more proteins (e.g., 
chaperones) and this pathway is triggered when the pathogen contacts a host cell. 
In addition, the production of some of the proteins to be exported is triggered when 
the contact secretion pathway is triggered. A defect in the pathway results in those 
proteins not being produced. 
Proteins contributing to virulence of streptococci are found in the cytoplasm, 
anchored to the bacterial surface, and extracellulariy. The mechanism of export of 
each of the proteins has not yet been identified. However, this is a growing area of 
investigation, and it is proposed that new drugs will be developed that will target 
certain steps in the exportation pathways. 
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This section will present current infomnation available regarding virulence 
proteins of streptococci. For sonne proteins, information about genetics, structure, 
and contribution to virulence is known; for other proteins, it is only known that they 
are produced by virulent isolates. 
Group A Streptococcus 
Many of the major protein virulence factors for GAS are under the regulation 
of one regulator called multiple gene regulator (mga). The gene products known to 
be under the control of this regulator are M protein, C5a peptidase, IgG binding 
protein, IgA binding protein, and serum opacity factor. Other gene products that 
may be under Mga control include cysteine protease (speB exotoxin) streptoccin A 
and oligopeptide permease. The Mga activity is sensitive to pH, temperature, CO2 
level, nutrient composition, and perhaps other factors."*® It Is proposed that mga is a 
two component regulatory system; however, no sensor has been identified.^^ Other 
proteins involved in virulence and produced by GAS are histone-like protein A 
(MpA), enzymes (e.g., DNAases, hyaluronidase, streptokinase, NADase, proteinase, 
amylase and esterase), hemolysins (streptolysin O and streptolysin S) and other 
exotoxins, speA, speC, and speF.^^ 
A major virulence protein for GAS is M protein. The M protein is a dimeric 
alpha helical surface protein. The carboxy terminal is located in the membrane and 
the amino terminal Is extracellular. The carboxy terminal is highly conserved and the 
amino terminal is variable. There are over 100 serotypes of M protein identified. 
Antibody to M protein is protective against homologous challenge, but there is little 
protection against a heterologous challenge.^® Typically, a GAS cell will have only 
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one type of M protein. Some M proteins are associated with induction of post­
streptococcal rheumatic fever and some are not/^ M protein is antiphagocytic and, 
therefore, a virulence factor. The M protein binds fibrinogen and complement 
inhibitor. Factor H. This prevents opsonization by complement and activation of the 
complement pathway. It is thought that M protein may have antiphagocytic activity 
in addition to inhibition of the complement system. In the absence of serum, 
phagocytosis was still inhibited. The mechanism for this inhibition of phagocytosis 
has not been identified.®®-^^ 
The IgG binding protein and IgA binding protein contribute to virulence. 
These proteins are common to many streptococci. They bind antibody via the 
antibody Fc receptor and camouflage the bacteria.'*^ ®^ 
C5a peptidase is indirectly an antiphagocytic virulence factor since it destroys 
C5a, which is a chemoattractant of neutrophils. By decreasing the number of 
neutrophils responding to the Infection, the bacteria have more time to replicate and 
establish an infection.^^ 
The role of serum opacity factor is unknown, but It Is associated with virulent 
strains and is regulated by mga.®® 
Three or four exotoxins are produced by GAS, speA, B, C, and 
exotoxin, speB is a cysteine protease. It has been shown by deletion mutants to be 
Important in virulence.^®'^ ® Immunization of mice with purified speB protected mice 
against subsequent challenge. However, It's exact role In virulence is unknown. 
Cysteine proteases have many activities Including cleavage of fibronectin and 
vitronectin,^^ and induction of IL1p production.^" These activities probably contribute 
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to invasion into the tissues. Spe B has also been reported to decrease the 
phagocytic activity of monocytes like cells and also induce apoptosis in that same 
cell line.^ Therefore, the Spe B may contribute to immune evasion. SpeA, C and F 
act as superantigens causing increased T cell activation and cytokine release and 
potentially life threatening clinical disease, other functions for these exotoxins have 
not been identified.®®-^ '^^ ® 
The two hemolysins produced by GAS are active under different conditions. 
Streptolysin O is an oxygen labile, thiol-activated hemolysin which is released 
extracellularly. This hemolysin binds to cholesterol and causes lysis of red blood 
cells and neutrophils. Streptolysin S is a serum and oxygen stabile cytotoxin. This 
toxin is found extracellulary and uses an oligonucleotide as a cam'er. The 
oligonucleotide is required for the toxin to have hemolytic activity.®® Streptolysin S 
causes lysis by binding to phospholipids of cell membranes and destabilizes them.^^ 
Finally, the HlpA histone-like protein has recently been described as a 
virulence factor for GAS. Besides binding to DNA in the cells, HlpA is released 
extracellularly and binds to heparin sulfate proteoglycans on many of the tissues. 
This protein may play a role in post-streptococcal disease causing 
glomerulonephritis.®^ 
Various enzymes are produced by GAS. These enzymes most likely help the 
bacteria to invade and damage surrounding tissues, increasing the nutrients 
available to the bacteria. These enzymes include nucleases, hyaluronidase, 
streptokinase, NADase, proteinase, amylase and esterase.®® '^ '^^ ® 
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Group B Streptococcus 
GBS have fewer proteins known to be associated with virulence than 
the GAS. The proteins that have been identified are considered to provide some 
virulence advantage to the GBS; however, their contribution is secondary to the 
major virulence factor, capsule. 
The major surface proteins are a antigen, p antigen, R protein and Rib 
protein.^ '^®^ The p antigen is an IgA binding protein.®^ No function has been 
identified for the other proteins. These proteins are thought to contribute to virulence 
because they are found on virulent isolates and antibodies to them are protective 
against challenge in mice. '^^ ® "*^ ®^ These proteins are not all found in all types of 
GBS. The a antigen and p antigen are found in types I and II and only in a lower 
percentage of the type III isolates.®® The Rib protein Is expressed on most of type III 
isolates and only on a low percentage of other isolate types.®^ R protein is found in 
a high percentage of type II and III clinical isolates.^^ 
GBS are p hemolytic and produce an intracellular protein with hemolytic 
activity.^® A hemolysis negative mutant was less virulent following intrathoracic 
Inoculation into an animal compared to the hemolytic parent.'*® A positive correlation 
has been made between the amount of hemolysin produced and the amount of lung 
damage, and the hemolytic activity is inhibited by phospholipids found in surfactant 
in the lung.^® It has been proposed that the hemolysin may have a role in Invasion: 
however, this has not been investigated. 
A C5a protease, like the one found in GAS, is also produced by GBS. Using 
C5 deficient mice and C5 competent mice, Bohnsack, et al., demonstrated that C5a 
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was important in recruitment of PMNs to sites of GBS infection and that strains that 
produced CSase attracted fewer polymorphonuclear cells (PMNs) to sites of GBS 
infection. It was proposed that the decrease in PMN recruitment allowed the 
bacteria extra time to multiply and spread before other mechanisms of recruitment 
could attract PMNs to the site.® 
Hyaluronidase, DNAase and neuraminidase are produced by some 
isolates.^ '^^ ® Based on research from other bacteria that produce these enzymes, 
they may contribute to GBS virulence. 
S. pneumoniae 
Several proteins produced by S. pneumoniae have been Identified as 
virulence factors. Like the other streptococci, S. pneumoniae produces several 
extracellular enzymes. S. pneumoniae produces lgA1 protease which may help it 
evade mucosal immune defenses as well as humoral defenses since this protease 
cleaves sIgA, IgG, and IgM. It produces neuraminidase, which may aid in the 
attachment of the bacteria to mucosal epithelium, hyaluronidase, which may aid in 
tissue destruction and neutrophil elastase inhibitor, which may aid in evasion of 
nonspecific immune system. '^^ ^ 
S. pneumoniae produces at least three different proteins that interact with the 
complement system. Two of the proteins are produced early in an infection and 
inhibit the complement system. One of the proteins is a Factor H binding protein 
and the other is a C3 degrading enzyme.^ The third protein that interacts with 
complement is pneumolysin. Pneumolysin is a thiol-activated hemolysin, similar to 
streptolysin O, and is found intracellulariy. The pneumolysin is considered a 
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virulence ^ctor based on antibody protection studies and pneumoiysin negative 
mutant mouse challenge studies.^ ® Pneumoiysin is released when the cells are 
undergoing autolysis, this occurs late in infection, during the stationary phase of 
growth. In addition to its hemolytic activity, pneumoiysin activates the classical 
pathway of complement. This is opposite of the effect the C3 degrading enzyme 
and the Factor H binding protein have on the complement system. The hypothesis 
for why both complement inhibiting and complement activating proteins would be 
produced is that suppression of the complement system early in infection allows the 
bacteria to replicate and then activation of the complement system later in the 
infection induces inflammation and helps the bacteria to disseminate throughout the 
host. '^^  
Autolysis of S. pneumoniae is seen in older cultures and occurs late in 
Infection, during the stationary phase of growth. The protein responsible for 
autolysis is autolysin. The autolysin is a surface protein that is activated during the 
stationary phase of bacterial growth, it may also be important in cell division. This 
enzyme breaks the bond between the NAM and alanine of the peptidoglycan. The 
autolysin can only act if teichoic acid containing choline is present.^^ It is thought 
that the autolysin uses the choline to dock and then it can act on the peptidoglycan 
bond. The autolysin produced by S. pneumoniae is considered a virulence factor 
because autolysin mutants are less virulent in mouse challenge studies. However, 
antibody to autolysin is not protective in challenge studies in mice. An explanation 
given for this is that autolysin contributes to virulence by causing the release of 
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intracellular virulence factors, e.g. pneumolysin, and autolysin antibody cannot 
neutralize this activity 
Another surface protein of S. pneumoniae is called pneumococcal surface 
protein A (PspA). The proposed function for PspA is to decrease bacterial clearance 
from the blood. Mutants deficient in PspA are less virulent than wild type, and 
antibody against PspA is protective in challenge studies in mice.^ '*^ 
S. suis 
Currently, there are no S. suis proteins with a proven function in virulence. 
However, many S. suis proteins that have been proposed to be involved in virulence. 
The two proteins that, for many years, were thought to be markers of virulence are 
extracellular factor (EF) and muramidase released protein (MRP). These two 
proteins were first identified by comparing protein profiles of S. suis isolates from 
tissues of diseased pigs with protein profiles of isolates from tonsils of healthy pigs. 
EF and MRP were found in the S. suis isolates from diseased pigs and not in most 
of the isolates from healthy pigs. The functions of EF and MRP are unknown, and 
the sequences do not have close homology to any known proteins. An MRP 
negative-EF negative mutant was not reduced in virulence compared to the parent. 
Therefore, it was concluded that EF and MRP were not required for virulence.®^ The 
author proposed that these two proteins may contribute to virulence, but when 
absent, other factors also contribute to virulence so no loss in virulence is observed. 
Another protein that has received recent attention as a potential virulence 
factor is the hemolysin. The hemolysin, suilysin, was described in 1994. It is a thiol-
activated, oxygen labile, pore-forming extracellular toxin. It has similarities to 
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streptolysin O, and antl-streptolysin antibody Inhibits the hemolytic activity of 
suilysin.^®'^ '^^ ® Immunization of mice and pigs with suilysin Induced protection 
against a homologous challenge.^^ However, anti-suilysin antibodies were not 
detected in pigs recovered from experimental challenge with a hemolytic Isolate. '^' It 
Is unclear whether suilysin has an antiphagocytic role and aids in survival of bacteria 
within a phagocyte, similar to other thiol-actlvated hemolysins expressed by other 
types of bacteria (e.g. listeriolysin). 
Some S. suis isolates hemagglutlnate red blood cells of a few species, horse 
and human.^ '^^  The hemagglutinating activity was found to be sensitive to 
protease treatment and to heat. Based on those results. It was proposed that the 
hemagglutinin was a protein; however, no protein with hemagglutinating activity has 
been Identified. There was no con-elation between hemagglutinating activity and 
virulence In mice. It Is unknown what role the hemagglutinin plays In virulence, but it 
Is thought It may contribute to adherence. Fimbriae are also present on all capsular 
types of S. suis}^ Similar to hemagglutinin, the Importance of the fimbriae has not 
been defined 
An adhesin for S. suis was found on all Isolates examined. The adhesin 
binds to galactosyl-(alpha 1-4)-galactose. The adhesin was Immunogenic and 
Induced In vitro bactericidal activity in blood. There was no correlation between the 
adhesin activity and the hemagglutinin activity. The authors propose that this 
adhesin should be Investigated as a vaccine candidate since it was present on all 
Isolates examined and it had good immunogenlcity.®^ 
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S. suis, like many other streptococci, has an IgG binding protein on its 
surface. It has been proposed that the IgG binding protein is a 52 kilodalton protein 
which is located on the cell surface and is also released extracellularly.^° The role in 
virulence is probably similar to that of other Fc receptors found on bacterial surfaces. 
They may camouflage the surface and interfere with opsonization and 
phagocytosis.®® However, there are no reports demonstrating the importance of this 
protein in virulence. 
In mice challenge studies, it was observed that S. suis grown in broth with 
serum was more virulent than S. suis grown in the broth without serum.®° This led to 
the identification of an albumin binding protein on the surface of S. suis. The 
albumin binding protein is thought to be a 39 kilodalton protein. The authors 
proposed that the binding of albumin to the surface of S. suis may increase its 
uptake and survival of the S. suis in phagocytes.®® However, albumin bound on the 
surface of S. suis may act as a camouflage for the bacteria. The definitive role of 
this protein in virulence has not been established. 
Considerable research is still required to define the role of S. suis proteins in 
virulence. 
Summary 
Streptococci have a wide variety of virulence factors. Research has provided 
important information for understanding the pathogenesis of streptococci, their 
means of evading the immune system, and what is required for a protective immune 
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response. This has led to a decrease in some of the diseases caused by 
streptococci. However, for many of the other streptococcal diseases a better 
understanding of the virulence factors of the bacteria is required before improved 
approaches to prevention and treatment can be designed. 
The purpose of the research described in this dissertaion was to gain a better 
understanding of S. su/s-induced disease and the interaction of S. suis with pig 
PMNs. 
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CHAPTER 3. DISEASE INDUCTION AFTER INTRANASAL CHALLENGE WITH 
STREPTOCOCCUS SUIS AND EVALUATION OF EFFICACY OF 
STREPTOCOCCUS PORCINUS VACCINE AGAINST S. SUIS CHALLENGE 
A paper to be submitted to Veterinary Microbiology 
Gayle B. Brown, James A. Roth, and Michael B. Roof 
Abstract 
The natural route of exposure of swine to Streptococcus suis Is oral/nasal; 
however, a reproducible model for Inducing clinical disease by intranasal (IN) 
inoculation of healthy pigs with S. suis alone has not been published. The published 
models for experimental S. su/s-induced disease are either intravenous or IN 
inoculation in pigs coinfected with another pathogen.®'^ ®'^ '^^ ® In order to evaluate S. 
suis vaccine efficacy or the in vivo influence of S. suis virulence factors, an IN 
challenge model not involving coinfection is preferred. The overall objectives of the 
experiments reported here were 1) to develop an experimental S. suis challenge 
model that would not require a second pathogen and would mimic the route of 
exposure, clinical signs and lesions of the natural disease, 2) to use the IN challenge 
model to evaluate the efficacy of a Streptococcus porcinus vaccine in protection 
against S. su/s-induced disease, and 3) to determine if in vitro passage reduced the 
virulence of the S. suis challenge strain. 
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The first experiment was designed to evaluate whether exposure to 
aerosolized S. suis would be better at inducing disease than IN inoculation, and 
whether irritation of the nasal mucosa by exposure to aerosolized ammonia prior to 
exposure to aerosolized S. suis would increase S. su/s-induced disease. A S. suis 
isolate recovered fi-om the meninges of a pig from a field case was used. The 
isolate was injected intravenously into a healthy pig. When this pig showed signs of 
central nervous system involvement, the brain and meninges were harvested, 
macerated, and frozen in aliquots for use as a stock culture to produce the challenge 
inocula. This stock culture was used for all the experiments in this work of study. 
The results of the first experiment indicated that direct intranasal administration of 
the S. suis after exposure to ammonia caused severe clinical disease which 
mimicked the natural S. su/s-induced disease and produced a high mortality rate. 
Exposure to aerosolized S. suis produced less severe disease, and exposure to 
aerosolized ammonia, before exposure to aerosolized S. suis, did not increase the 
severity of the disease. 
The second experiment was designed to evaluate the importance for disease 
induction of nasal mucosa irritation by exposure to aerosolized ammonia prior to IN 
inoculation of S. suis, and to evaluate the efficacy of a live avirulent S. porcinus 
vaccine against S. suis challenge. The results indicated that exposure to aerosolized 
ammonia before IN challenge with S. suis did not increase the severity of the 
disease induced. The pigs that received the live avirulent S. porcinus vaccine had a 
lower incidence of disease; however, the differences were not statistically significant. 
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it was concluded that S. porcinus vaccine was not a good candidate for inducing 
protection against S. su/s-induced disease. 
The third experiment was designed to determine if in vitro passage of the S. 
suis challenge strain would reduce its virulence. One group of pigs was exposed by 
IN inoculation to passage 1 S. suis. The other group was exposed by IN inoculation 
to the same isolate that had been serially passed on blood agar plates 20 times. 
There were no significant differences in incidence or severity of disease between 
these two challenge groups. Therefore, 20 passages in vitro did not effect the 
virulence of the S. suis serotype 2 isolate used as a challenge inoculum. 
General Introduction 
Streptococcus suis (S. suis) can colonize the tonsils of pigs at birth and is 
commonly isolated from clinically healthy pigs.^ In many pigs it remains in the tonsil 
without causing disease.® However, in some pigs the bacteria invade causing a 
septicemia resulting in meningitis, arthritis, pericarditis, peritonitis, pleuritis, and/or 
pneumonia.^® S. suis can cause mortality rates of 5% to 15% in nursery age pigs.^° 
It is not understood why some isolates remain in a commensal relationship 
with the host, while others invade and kill the host. Often, S. su/s-induced disease 
occurs when other stressors are present. For example, there is an increased 
incidence of S. su/s-induced disease at weaning, when slurry gasses are high, 
and/or in pigs with porcine reproductive and respiratory syndrome virus (PRRSV) 
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infection.^ The virulence factors for S. suis are poorly understood. Several 
potential virulence factors have been identified including capsule, murannidase-
released protein, extracellular factor, hemolysin, and hemagglutinins.®-^^" '^*-^®'^ "^^ 
However, only capsule has been demonstrated by isogenic mutants to be required 
for virulence.® Elimination of S. suis infection and prevention of S. sa/s-induced 
disease through management practices, medication, or vaccination have not been 
very successful.^ 
In order to better understand the pathogenesis of S. su/s-induced disease, 
and to evaluate virulence factors and new prevention and treatment regimes, 
challenge models of infection that, as closely as possible, mimic the natural route of 
exposure and disease process are required. The natural route of exposure to S. 
suis is predominately oral/nasaP®; therefore, invasion of the mucosal surface is an 
important step in the pathogenesis of the disease. A reproducible challenge model 
for inducing clinical disease with S. suis alone by experimental intranasal inoculation 
in a healthy pig has not been published. The published models for experimental 
production of S. su/s-induced disease are intravenous or intranasal exposure to S. 
suis in pigs coinfected with pseudorabies virus, PRRSV, or Bordetella 
bronchiseptica. '^^ '^^ '^^  The intravenous model is useful for studying S. suis 
septicemia; however, it bypasses the process of S. suis colonization and invasion 
across the mucosal surface. The coinfection models are important for evaluation of 
pathogen interactions. These are valuable models for evaluating prevention and 
treatment regimes for coinfections. However, in order to evaluate S. suis vaccine 
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efficacy, or the in vivo influence of S. suis virulence factors, an intranasal challenge 
model not involving coinfection is preferred. 
The objective of the research reported here was to develop an intranasal S. 
suis serotype 2 challenge model. A satisfactory model was defined as one that 
could cause clinical disease in at least 80% of the animals and not require 
coinfection with a second pathogen. The objectives of the individual experiments 
were: experiment 1) to determine if S. suis serotype 2, isolate ISU VDL #40634/94 
induces clinical disease when administered by aerosolization and to determine 
whether irritation of the nasal mucosa using ammonia would increase the 
susceptibility of pigs to S. suis administered by aerosolization: experiment 2) to use 
an intranasal S. suis challenge model to evaluate the efficacy of Streptococcus 
porcinus as a vaccine to prevent S. su/s-induced disease and to determine if 
aerosolized ammonia was needed in the intranasal challenge model; and 
experiment 3) to evaluate and compare the clinical disease caused by a virulent S. 
suis isolate before and after 20 passages in vitro. 
Experiment 1 
Introduction 
S. suis serotype 2 was selected for use in the development of this challenge 
model because it is one of the serotypes commonly isolated fi'om diseased animals. 
Based on reports that S. suis inoculated intranasally into healthy pigs would not 
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induce disease consistently, the culture was allowed to grow to maximal 
numbers/®'^ ^ Pigs were exposed to S. suis either by direct intranasal administration 
or by aerosolization in a closed chamber. The hypothesis was that aerosolized 
bacteria would mimic natural exposure and allow distribution of the bacteria 
throughout the respiratory tract. It was also hypothesized that exposure of pigs to 
ammonia fumes would mimic exposure to slurry gases and, therefore, increase the 
susceptibility of the pigs to S. su/s-induced disease without introduction of a second 
pathogen. 
Materials and Methods 
Animals 
Eighteen, clinically healthy four-week-old commercial crossbred pigs from a 
herd negative for PRRSV and with no known history of S. sa/s-induced disease were 
used. Pigs were removed from the sows (weaned 12 to 18 days of age) and allowed 
to acclimate for six days. Each group was housed in a separate pen in the same 
airspace. Pigs were fed adiib a nonmedicated commercial ration that met the 
National Research Council (NRC) requirements for the age and weight of the pigs. 
Tonsil swabs were obtained from each pig prior to S. suis exposure and were 
screened for S. suis serotype 2 (described below). Although S. suis was recovered 
from the tonsils of almost all the pigs, none of the isolates tested were serotype 2. 
Experimental design 
Three groups of six animals were used. One group was exposed in a 
chamber to aerosolized S. suis only. The second group was exposed in a chamber 
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to aerosolized ammonia prior to exposure to aerosolized S. suis. The third group 
was exposed in a chamber to aerosolized ammonia and then to S. suis by intranasal 
inoculation (Table 1). Rectal temperatures and clinical scores for central nervous 
system (CNS) signs, swollen joints/lameness, and lethargy were recorded daily. 
Moribund animals and animals still alive on the scheduled day for necropsy (Day 14 
following challenge) were euthanized with Beuthanasia D™ (Schering-Plough) 
intravenously. All pigs were necropsied and tissues swabbed for bacterial isolation 
(described below). 
S. suis challenge inoculum 
S. suis serotype 2 isolate ISU VDL#40634/94 was obtained from a field case 
of meningitis in a pig submitted to the Iowa State University (ISU) Veterinary 
Diagnostic Laboratory (VDL) in 1994 (case number 40634). The field isolate was 
grown in Todd-Hewitt broth (THB) (Difco) containing 5% heat inactivated fetal calf 
serum (hiFCS) for five hours at 37°C in 5% CO2 air. The bacteria were pelleted by 
centrifugation and resuspended to a concentration of 10®-^ colony forming units 
(cfu)/milliliter (ml) in RPM11640. One ml was inoculated intravenously (IV) into a 
healthy weaned pig. When the pig began to show CNS signs (at 24 hours after IV 
inoculation), it was humanely euthanized. The infected brain and meninges were 
collected aseptically. A 10% homogenate of the brain and meninges was prepared 
in THB with 20% glycerol using a Stomacher 80 lab blender (Seward, Inc., England). 
One and one half ml aliquots were made and stored frozen at -80°C. This 
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brain/meninges homogenate was the stock material for preparing the experimental 
bacterial challenge inoculum used in all three experiments. 
The brain/meninges homogenate was thawed and streaked, using a sterile 
cotton-tipped applicator, onto three plates of tryptose agar containing 5% bovine 
blood (BAP), and Incubated for 15 hours at 37°C in 5% CO2 air. Each plate 
contained approximately 300 colonies of S. suis. All the colonies on the BAPs were 
removed with a cotton swab and transferred to six ml THB containing 5% hiFCS. 
After a two hour incubation at 37°C in 5% CO2. the six ml culture was added to 24 ml 
of wanned THB containing 5% hiFCS. After another two hour incubation, a 1:17 
dilution of this culture was made in warmed THB containing 5% hiFCS. This culture 
was incubated an additional 3.5 hours then placed on ice until the pigs were 
inoculated (within 1 to 2 hours). The inocula were checked for purity by streaking 
onto a BAP and incubating at 37°C in 5% CO2- The cfli/ml of bacteria in the culture 
was detennined. The challenge inocula for all three experiments were prepared in 
this manner, unless otherwise described. Pigs receiving aerosolized S. suis were 
placed in a four by six by two feet chamber. The challenge inoculum was 30 ml of S. 
suis (1.6x10® cfu/ml) aerosolized into the chamber for a 30 minute period. Pigs that 
received S. suis via direct intranasal inoculation were inoculated with 2 ml (1 
ml/nostril) of 1.6 x 10® cfu/ml. 
Ammonia pretreatment 
Ammonium hydroxide (1:5 dilution of reagent grade ammonium hydroxide. 
Fisher, Inc.) was aerosolized at 25 PSI using a nebulizer into a four by six by two 
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feet chamber containing six pigs. The ammonium concentration was approximately 
100-150 ppm over a 30 minute period as determined by Sensidyne Gastec Detector 
Tube, (Animal Environment Specialists, Inc., Columbus, OH). The ammonia level in 
the chamber was then lowered by ventilation. 
Observations and sampling 
Rectal temperatures and clinical scores were recorded daily. Clinical scores 
were recorded for CNS signs (tremors, head tilt, convulsions, and paddling), swollen 
joints/lameness, and lethargy using a scale of 0-3 with 0 = normal, 1 = mild, 2 = 
moderate, and 3 = severe. Moribund animals and animals still alive on the scheduled 
day for necropsy were euthanized with Beuthanasia D™ (Schering-Plough) 
intravenously. The observations and sampling methods described here were used 
in all three experiments. 
Necropsy 
The tonsil, lung, pleura, peritoneum, pericardium, liver, spleen, ]oint(s), and 
brain/meninges were examined for macroscopic lesions. Swabs for bacterial culture 
were also collected from these tissues. 
Bacteriology 
Swabs from tissues obtained at necropsy and tonsil swabs obtained, prior to 
the study were swabbed onto BAPs. They were then incubated at 37°C in 5% CO2 
air for 24 to 48 hours. One colony from the cultures of internal tissues and three 
different colonies from the tonsil cultures were selected. Subcultures were tested for 
catalase reaction. Gram stain, Voges-Proskauer reaction, growth in 6.5% NaCI, and 
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production of amylase. The subcultures that were catalase negative, Gram stain 
positive, Voges-Proskauer reaction negative, did not grow in 6.5% NaCI, and were 
positive for the production of amylase were considered to be S. suis. Ail S. suis 
isolates were then checked for serotype 2 reactivity using the coagglutlnation test. '^^ ° 
This bacterial testing was done for experiments one and two. For experiment three, 
moderate to heavy growth of streptococcus-like, a-hemolytic colonies were selected 
and subcultured. The subcultures were checked for serotype 2 reactivity using the 
coagglutlnation test. 
Statistical Analysis 
Differences In frequency of abnomnal clinical signs, S. suis Isolations, and 
mortality were analyzed by chl-square. This type of analysis was used for all three 
experiments. 
Results 
An animal was considered to have a fever If It had any recorded rectal 
temperature of > 104.5°F. The number of animals In each group that had a fever 
after Inoculation with S. suis Is recorded In Table 2. An animal was considered to 
have CNS Infection If it had clinical signs of tremors, head tilt, convulsions and/or 
paddling, and/or S. suis Isolation from the braln/menlnges. An animal was 
considered to have joint Infection If It had swollen jolnt(s), and/or lameness that did 
not exist before challenge, and/or S. suis Isolation from the joint. The number of 
animals in each group with clinical signs or positive cultures from the CNS or joint(s), 
are also shown In Table 2. An animal was included In the last column of Table 2 
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(any evidence of infection) if it had any one of the following: fever, CNS signs, joint 
infection, lameness, lethargy, or S. suis cultured from any tissue other than tonsil. 
Table 3 shows the number of animals in each group that had S. suis serotype 
2 cultured from the various tissues swabbed at necropsy. A summary column of the 
total number of animals in each group that had S. suis serotype 2 cultured from an 
intemal tissue (not tonsil) is also included in Table 3. Figure 1 presents the 
cumulative mortality in each group. 
Discussion 
All groups had at least 80% of the pigs with some evidence of infection. 
However, only one-half of the pigs in the aerosolized S. suis groups developed 
evidence of S. suis septicemia (isolation of S. suis from an intemal organ). Irritation 
of the nasal mucosa using aerosolized ammonia did not enhance the disease 
caused by S. suis when the organism was administered by aerosolization into a 
chamber. S. suis administered intranasally following irritation of the nasal mucosa 
with ammonia gas caused severe S. su/s-induced clinical disease. More animals 
had clinical disease, and S. suis was isolated from more tissues in animals 
inoculated intranasally compared to those exposed to aerosolized S. suis. An 
intranasal S. suis only group was not included in this experiment. Therefore, it was 
not determined if the aerosolized ammonia contributed to the disease progression in 
the pigs exposed to S. suis by intranasal inoculation. 
The difference between the disease caused by the aerosolization and 
intranasal inoculation of S. suis exposures was probably due to a difference in dose 
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received by each animal. Aerosolization of the S. suis should help the S. suis pass 
deeper into the respiratory tract, but the dose received by each animal is unknown. 
In comparison, intranasal inoculation introduces a large number of bacteria into the 
nasal and oral cavity. Based on the results of this study, it is important to have a 
large number of bacteria introduced into the nasal cavity. It does not appear to be 
important to have the S. suis aerosolized into small droplets for inhalation deep into 
the lungs. Therefore, in subsequent experiments for development of an intranasal 
S. suis only challenge model, S. suis was not aerosolized. 
Experiment 2 
Introduction 
Streptococcus porcinus is a Group E Streptococcus that is capable of 
colonizing tonsils and causing cervical abscesses in pigs. In the1970s an attenuated 
live S. porcinus vaccine was developed and found to be effective for prevention of 
cervical abscesses.® Due to changes in swine management practices, the use of 
the attenuated live culture vaccine, and/or antibiotics in feed. S. porcinus-mduced 
disease is now rarely observed. As a result, the vaccine is no longer used.^^ 
The protection that was provided by the attenuated live S. porcinus vaccine 
was thought to be due to an immune response to antigens present in many different 
serotypes, and not to serotype specific capsular antigens.^^ S. suis is a group D 
streptococcus: however, it and may have virulence factors and important 
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immunogens similar to S. porcinus. The hypothesis tested in this experiment was 
that S. porcinus vaccine induces an immune response that protects pigs from 
developing S. su/s-induced clinical disease. 
There were two objectives for this study. One objective was to evaluate an 
attenuated live S. porcinus vaccine for efficacy against virulent S. suis administered 
intranasally. The other objective was to determine if ammonia pretreatment (as 
performed in experiment 1 above) was required for clinical disease to develop after 
intranasal inoculation of S. suis, isolate ISU VOL #40634/94. 
Materials and Methods 
Animals 
Forty clinically healthy three- to four-week-old commercial crossbred pigs 
from a herd negative for PRRSV and with no known history of S. sa/s-induced 
disease were used. Pigs were removed from the sows (weaned 12 to 18 days of 
age) and allowed to acclimate to the isolation rooms for four days. Pigs were fed ad 
lib a nonmedicated commercial ration that met the NRC requirements for the age 
and weight of the pigs. All vaccinated pigs were in one room, and unvaccinated pigs 
were in another until the day of S. suis challenge. On the day of S. suis challenge, 
all pigs challenged with S. suis (both vaccinated and unvaccinated) were put in the 
same room, but in separate pens. All pigs not exposed to S. suis were housed in a 
separate room. Tonsil swabs were obtained from each pig prior to S. suis exposure, 
screened for S. suis serotype 2 (as described for experiment 1), and found to be 
negative. 
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Experimental design 
Four groups of 10 pigs were used (Table 4). Group 1 received S. porcinus 
vaccination at three to four weeks of age. Two weeks following vaccination, group 1 
was exposed in a chamber to aerosolized ammonia for 30 minutes (as described for 
experiment 1), and then inoculated intranasally with S. suis. Group 2 served as 
unvaccinated controls and was exposed in a chamber to aerosolized ammonia then 
inoculated intranasally with S. suis. Group 3 was part of the challenge model 
development This group was challenged with S. suis intranasally, without exposure 
to aerosolized ammonia. Group 4 served as a negative control and did not receive 
any treatment. Rectal temperatures and clinical scores were recorded daily. 
Moribund animals and animals alive on the scheduled day for necropsy (14 days 
after S. suis exposure) were euthanized. The observations, samplings, bacteriology 
and necropsies were done as described in experiment 1. 
S. porcinus vaccine 
S. porcinus ATCC isolate #21223 was used to make the vaccine, and the 
vaccine was prepared by NOBL Laboratories, Inc., Sioux Center, Iowa.. The S. 
porcinus avirulent live culture vaccine was grown in Brain Heart Infusion broth 
supplemented with 10% fetal calf serum. The culture was lyophilized and tested for 
sterility and purity. The bacteria were rehydrated to a dose of > 1 x 10® CFU per 
dose. Group 1 was vaccinated Intranasally (1 ml/nostril) with 2 x 10® cfu of S. 
porcinus on Day 0 of the study. Pigs were three to four weeks of age when they 
were vaccinated. 
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S. suis challenge inoculum 
S. suis serotype 2, isolate ISU VDL #40634/94 was prepared as described in 
Experiment 1. The titer of the S. suis inoculum was 1.4 x 10® cfu/ml. Pigs in Groups 
1, 2, and 3 were exposed to S. suis serotype 2, isolate ISU VDL #40634/94 by 
intranasal inoculation of 1 ml of the bacteria in growth media into each nostril on Day 
14 of the study. 
Results 
Effect of attenuated live S. porcinus vaccination 
There were no abnormal clinical signs or elevated rectal temperatures 
recorded during the two-week observation period following S. porcinus vaccination 
that could be attributed to the vaccine. Joint swelling was observed in some 
vaccinated and nonvaccinated animals, suggesting it was probably not associated 
with vaccination. Ataxia was observed in one vaccinated animal beginning on Day 9 
following vaccination. The animal was euthanized on Day 11 due to severe CNS 
signs; however, no gross lesions were found at necropsy, and there was no bacterial 
growth on cultures of meninges or other organs at necropsy. No histologic evidence 
of meningitis or encephalitis was found. No cause of clinical signs was identified. 
Results following S. suis challenge 
Vaccine efficacy. There were no significant differences between the 
vaccinated and unvaccinated pigs following challenge with intranasal S. suis (Tables 
5 and 6). Both groups developed clinical signs of S. su/s-induced disease and had 
S. suis cultured from similar intemal tissues (Tables 5 and 6). The vaccinated group 
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had lower mortality (Figure 2) and a lower incidence of S. suis cultured from intemal 
tissues than the unvaccinated group, however, the differences were not statistically 
significant. 
Challenge model development The unvaccinated pigs challenged by 
intranasal inoculation of S. suis, with or without preexposure to 100-150 ppm 
ammonia fumes in the air for 30 minutes, were compared based on clinical 
observations, rectal temperatures, mortality, and necropsy/bacteriology findings. 
Both groups showed mild/moderate lethargy in 90% of the pigs. Pigs that were 
exposed to aerosolized ammonia prior to challenge started to show clinical signs 
sooner than the group that were not exposed. The group that was exposed to 
aerosolized ammonia prior to challenge had peak clinical signs and fever on Days 2 
and 3 following exposure to S. suis. The group that was not exposed to aerosolized 
ammonia had peak clinical signs and fever on Days 4 and 5 following challenge 
(data not shown). The mortality in the pigs that were exposed to aerosolized 
ammonia occurred on Days 3 and 5 following exposure to S. suis (Figure 2). 
Mortality In the pigs exposed to S. suis only occurred on Days 4, 6, and 9 after 
challenge. The onset of clinical signs and mortality both indicate a more rapid 
progression of disease in the pigs exposed to aerosolized ammonia; however, the 
overall outcome was not significantly different. 
Discussion 
Avirulent live culture S. porcinus intranasal vaccination did not provide 
adequate protection against S. suis serotype 2 clinical disease. Vaccination did 
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reduce the incidence of mortality, recovery of S. suis, and clinical signs after S. suis 
challenge. However, this was not statistically significant. Further development of this 
vaccine for protection against S. su/s-induced disease was not pursued, since this 
level of protection was not acceptable. 
Intranasal Inoculation of S. suis with or without exposure to aerosolized 
ammonia produced similar clinical disease, fever, and mortality. The exposure to 
aerosolized ammonia resulted in a more rapid onset of disease. Based on the 
results of this and previous experiments, it was decided that the S. suis challenge 
model that was the least complex and still mimicked natural disease was intranasal 
administration of approximately 2 X 10® cfu of ISU VDL #40634/94 S. suis serotype 
2 without any pretreatment required. With this model, clinical disease occurred in a 
majority of the animals. This model mimics the natural disease in that it requires the 
challenge bacteria to colonize and invade the mucosa. It should be a good model 
for evaluating S. suis pathogenesis, vaccine efficacy, and treatment regimes 
Experiment 3 
Introduction 
The previous experiments demonstrated that intranasally administered S. suis 
serotype 2 (isolate ISU VDL #40634/94) induced disease which mimicked naturally 
occurring disease. Previous publications reporting S. suis challenge models indicate 
that S. suis administered intranasally to healthy pigs does not consistently induce 
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disease similar to that observed in the field.®*^®'^ ^ The reason for the difference in 
these two observations is not clear. The challenge bacteria used in our previous 
experiments were preserved as a frozen homogenate of brain and meninges from a 
pig showing clinical signs of meningitis after intravenous challenge. It was 
hypothesized that the isolate we used was virulent because it was stored fi'ozen as a 
brain/meninges homogenate and the challenge inoculum was produced without 
further passage. It was further hypothesized that In vitro passage of the bacteria 
would decrease its virulence in pigs. The objective of this study was to evaluate and 
compare the clinical disease caused by a virulent S. suis serotype 2 isolate ISU VDL 
#40634/94 before and after 20 passages in vitro on a solid media. 
Materials and Methods 
Animals and experimental design 
Twenty commercial crossbred pigs from herds negative for PRRSV were 
used. Pigs were removed directly from the sows (weaned 12 to 18 days of age) and 
allowed to acclimate to the isolation rooms for 10 days. The pigs were injected 
intramusculariy with Excenel™ (Pharmacia & Upjohn Co., Kalamazoo, Ml) once a 
day for three days immediately following their anival at the Isolation facilities. The 
pigs were inoculated intranasally with S. suis when they were between 22 and 28 
days of age. 
One group of 10 pigs received Passage 1 (PI) of S. suis serotype 2 isolate 
ISU VDL#40634/94 intranasally, and one group of 10 pigs received Passage 20 
(P20) of S. suis serotype 2 isolate ISU VDL#40634/94 intranasally. The two groups 
53 
were housed on raised decks in separate isolation rooms. Rectal temperatures and 
clinical scores were recorded daily for each animal. Moribund animals and animals 
still alive on the day scheduled for necropsy were euthanized. At necropsy, tissues 
were swabbed and cultured for S. suis serotype 2. Observations, sampling, 
bacteriology and necropsies were perfomned as described in experiment 1. 
Bacteria 
S. suis serotype 2, isolate ISU VDL #40634194 was used as the challenge 
bacterium. This isolate was obtained and a stock culture prepared as described in 
experiment 1. 
The P1 challenge inoculum was prepared as described in experiment 1. The 
P20 challenge inoculum was prepared by serially passaging the stock bacteria daily 
on BAPs for a total of 20 days. A single colony was picked each day and streaked 
onto a BAP. No morphologic changes were noted during the passaging. All 
colonies on day 20 were removed from the BAP with a cotton swab and placed in 
THB containing 20% glycerol, aliquoted to 1.2 ml volume, and then stored frozen at 
-80°C. P20 culture for inoculation of pigs was grown the same as described for P1. 
Pigs were Inoculated intranasally with 2 ml (1 ml/nostril) of 1 x 10® cfu of bacteria per 
ml of growth media. 
Results 
The clinical disease caused by intranasal inoculation of PI and P20 was 
similar (Table 7). Distribution of S. suis in the tissues also was similar between the 
two groups (Table 8). There was 60% mortality prior to the scheduled day of 
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necropsy in the P20 group and 40% mortality in the P1 group (Figure 3). No 
significant {p>0.05) differences were detected between the two different challenge 
groups for any of the parameters measured. 
Discussion 
In vitro passaging is a common method for reducing the virulence of 
pathogens. However, 20 passages in vitro for S. suis isolate ISU VDL #40634/94 
did not result in any detectable loss in virulence. It is unknown whether virulence 
would be altered with a higher number of passages, alternate media or different 
growth conditions. The working hypothesis was that the preservation of the stock 
challenge bacteria in frozen brain/meninges homogenate without passage 
contributed to its ability to induce disease when administered intranasally to healthy 
pigs. Based on the results of this experiment, the in vitro passaging of this isolate 
did not cause any loss in virulence. Therefore, it remains unclear as to why this 
challenge preparation of S. suis is apparently more successful at inducing disease 
after intranasal administration than other reported isolates. 
Another Important outcome of this experiment was that the P1 challenge 
results were similar to previous challenge results. This confirms our previous results 
with this challenge model and indicates that this model is reproducible. 
The reason for the success of this challenge model is not clear. Some 
possibilities are: unique attributes of the isolate, the number of bacteria in the 
challenge inoculum, that the isolate was administered in growth media without 
washing, or the way the inoculum was grown. 
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This isolate may have some special attributes/virulence mechanisms that 
isolates used in previously published intranasal challenge studies did not have. It 
has been demonstrated that different isolates of S. suis serotype 2 differ in their 
ability to produce disease. However, the basis for the differences is unknown. The 
isolate used in this research was recovered from the brain of a pig showing signs of 
meningitis. However, the ability to produce disease in a field case does not 
necessarily mean it will produce disease in an experimental setting. The DH5 strain 
used by Galina, et al and the D282 strain used by Vecht, et al were both recovered 
from the brain of a pig showing signs of meningitis and under their challenge 
conditions neither strain caused clinical signs in healthy pigs.®'^ ^ 
The titer of the challenge inoculum may contribute to the success of this 
challenge model. A titer of 10" cfu per pig was used. This titer is higher than the 
10^ cfu per pig titer used by Galina, et al® and higher than the 2 x 10® cfu per pig titer 
used by Vecht, et al.^^ No clinical disease was observed following intranasal 
challenge with S. suis at those titers. Iglesias, et al used a titer of 10® cfu per pig.^® 
In that study, 50% of the pigs showed clinical signs of S. st//s-induced disease and 
bacteria were cultured from internal tissues of those animals; however, there were 
no CNS signs induced and no mortality. In a separate study by Thanawongnuwech, 
et al^ ®, using isolate ISU VDL #40634/94 grown using the same method described In 
experiment 1 of this paper, the 10® cfu per ml culture was diluted 1:10 using Hank's 
Balanced Salt Solution. When the diluted culture of 10® cfu per ml was inoculated 
intranasally into healthy pigs, only 14% developed clinical S. su/s-induced disease. 
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This indicated that either the titer of bacteria or inoculation in undiluted growth media 
may be important. The titer of 10® cfu per ml was only achieved when heat 
inactivated fetal calf serum was added to the Todd Hewitt broth, and the bacteria 
were grown using several feeding steps. This method of growth may contribute to 
the virulence of the bacteria. Iglesias et aP®, reported that the challenge bacteria 
used was grown on agar and then in broth, but the times were not included. The 
growth conditions for the bacteria used by Galina et al®, were not described. Vecht 
et al^ \ grew the bacteria on agar then in broth for 18 hours and then added fresh 
broth and incubated for an additional 6 hours. Since, all of the methods for growing 
the bacteria were different it is possible that this influenced the outcome of intranasal 
S. suis challenge. 
Another possibility for the virulence of the challenge model reported here is 
that there are important virulence factors in the growth media that allow the bacteria 
to successfully colonize and invade. In the published reports of S. suis intranasal 
challenge, it is not clear if the bacteria were administered in growth media or if the 
bacteria were washed before administration.®*^®'^ ^ As mentioned above, when ISU 
VDL #40634/94 was grown to 10® cfu and then diluted 1:10 in Hank's Balanced Salt 
Solution, the in vivo virulence was greatly reduced.^® 
Finally, the susceptibility of the pig may contribute to the differences 
observed. We challenged five to six week old pigs that were weaned directly from 
the sow into isolation facilities. In the other reports, pigs were 9 weeks old, 7 days 
old, or 3 weeks old. The 7 day old pigs were cesarean derived pigs and did not 
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receive colostrum^^ so maternal antibody interference cannot explain their lack of 
susceptibility. The pigs challenged at 3 weeks of age may have had maternal 
antibody that interfered with their susceptibility to S. su/snnduced disease.^ Some 
of the 9-week-old pigs were susceptible to the S. suis alone (50% clinical disease)^®; 
the increased age may have decreased the susceptibility of some of the pigs in that 
experiment compared to younger pigs used in these studies. 
Further study is required to determine why this experimental intranasal S. suis 
challenge model is successful in inducing disease. Evaluation of challenge with 
10^cfu of S. suis in PBS compared to 10® cfu in growth media would indicate the 
importance of factors in the growth media. A study comparing different 
concentrations of S. suis in growth media as the challenge Inoculum would help 
clarify the importance of the challenge titer. It would be interesting to obtain other 
Isolates and grow them like the ISU VDL #40634 isolate is grown to see if the 
method of growing the bacteria influences the in vivo virulence of the isolates. 
Finally, challenge of different ages of pigs obtained from the same source would 
provide information regarding age influence on susceptibil'ity. 
Summary and Conclusions 
A reproducible intranasal S. suis challenge model is described. Clinical signs 
of S. su/s-induced disease begin a few days after intranasal inoculation, indicating 
that colonization and invasion are part of this model. The resulting disease mimics 
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naturally occurring S. suis induced clinical signs and lesions. This model is 
successful without aerosolization of the bacteria. Irritation of the nasal mucosa 
using aerosolized ammonia is not needed nor is coinfection with a predisposing 
pathogen. Twenty passages in vitro does not change the virulence of this isolate. 
Based on comparisons to other reports, it appears that titer and/or growth media in 
the inocula is important for Intranasal challenge to induce disease.®-^®-^®-^^ 
Finally, using this intranasal S. suis challenge model, S. porcinus avirulent 
live vaccine was evaluated for efficacy against S. su/s-induced disease. The S. 
porcinus vaccine reduced S. sa/s-induced disease incidence, but not significantly. 
This degree of efficacy was judged to be inadequate to pursue it as a vaccine for 
protection against S. st//SHnduced disease. 
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Table 1. Experimental design for experiment 1. 
Group Number Pretreatment Route of S. suls Necropsy (days 
of pigs administration after challenge) 
1 6 None Aerosolized In a chamber 14 
2 6 Ammonia fumes Aerosolized in a chamber 14 
3 6 Ammonia fumes Intranasal inoculation 14 
Table 2. Number of pigs in each group from experiment 1 that had evidence of fever, CNS infection, joint infection, or 
any of these three signs and/or lethargy after S. suis challenge exposure. 
Group Fever (> 104.5°F) 
CNS Infection (clinical signs 
and/or culture positive) 
Joint Infection (clinical 
signs and/or culture 
positive) 
Number of Animals with 
Evidence of S. suls 
infection 
Aerosolized S. suls 4/6 3/6 1/6 5/6 
NHa pretreatment 
aerosolized S. suls 
4/6 2/6 1/6 5/6 
NH3 pretreatment 
+ intranasal S. suis 
5/6 5/6 4/6 5/6 
There were no significant differences between groups. 
Table 3. Number of pigs in each group from experiment 1 that were culture positive for S. suis serotype 2 from tissues 
swabbed at necropsy. 
S. suis 
from 
interna 
tissue 
Group Internal Tonsil Lung PIra Perlt Peric Liver Spleen Joint CNS 
Aerosolized 
S. suis 
NHa pretreatment 
+ aerosolized 
S. suis 
3/6 3/6 1/6 1/6 1/6 0/6 0/6 0/6 1/6 2/5 
3/6 3/6 0/6 0/6 0/6 0/6 1/6 0/6 1/6 2/6 
NHa pretreatment 
+ intranasal 
S. suis 5/6 5/6 1/3 2/6 2/6 4/6 2/6 2/6 4/6 5/6 
PIra = pleura 
Perit = peritoneum 
Peric = pericardium 
There were no significant differences between groups. 
Table 4. Experimental design for experiment 2. 
Group # of pigs Vaccination Pretreatment Intranasal Challenge 
1 10 S. porcinus Aerosolized Ammonia S. su/s 
2 10 None Aerosolized Ammonia S, su/s 
3 10 None None S. suis 
A 10 None None None 
Table 5. Number of pigs in each group from experiment 2 that had evidence of fever, CNS infection, joint infection, or 
any of these three signs and/or lethargy after S. suis challenge. 
CNS Infection (clinical Joint Infection (clinical Number Animals with 
Fever signs and/or culture signs and/or culture Evidence of S. su/s 
Group (> 104.5 °F) positive) positive) Infection 
Vaccinated, NHspretreatment ..q# ..Qb 
+ S.suis\N 
Unvaccinated, NH3 pretreatment e/-ob H/m 
+ S. suis IN 9/10" 
Unvaccinated, S. suls IN 7/10" 5/10" 2/10 9/10" 
Control 0/10 0/10 0/10 0/10 
"p< 0.05 compared to control 
"p < 0.01 compared to control 
There were no significant differences between vaccinated and unvaccinated animals that were challenged with S. suis. 
Table 6. Number of pigs in each group from experiment 2 that were culture positive for S. suis serotype 2 from tissues 
swabbed at necropsy. 
Group S. suis from Tonsil Lung PIra Peril Peric Liver Spleen Joint CNS 
internal tissue 
Vaccinated, NHs 
pretreatment 
+ S. suis IN 2/9 6/9" 1/9 0/9 0/9 2/9 0/9 2/9 1/9 2/9 
Unvacclnated, 
NHa pretreatment 
+ S. suis IN 4/10' 5/10" 3/10 0/10 0/10 2/10 0/10 2/10 0/10 4/10" 
Unvacclnated, 
S. suis IN 5/10" 1/10 2/10 0/10 0/10 1/10 0/10 1/10 2/10 5/10" ^ O) 
•>1 
Control 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/10 0/10 
PIra = Pleura 
Perit = Peritoneum 
Peric = Pericardium 
®p< 0.05 compared to control 
"p < 0.01 compared to control 
There were no significant differences between vaccinated and unvacclnated animals that were challenged with S. suis. 
Table 7. Number of pigs in each group from experiment 3 that had evidence of fever, CNS infection, joint infection, or 
any of these three signs and/or lethargy after S. suis challenge exposure. 
Fever CNS Infection (clinical signs Joint Infection (clinical signs Any evidence of 
Group (> 104.5 °F) and/or culture positive) and/or culture positive) S. suls Infection 
S. suls P1 9/10 6/10 8/10 10/10 
S. suis P20 8/10 7/10 7/10 10/10 
There were no significant differences between the groups. 
O) 
oo 
Table 8. Number of pigs in each group from experiment 3 that were culture positive for S. suis serotype 2 from tissues 
swabbed at necropsy. 
Group S. suis 
from 
Internal 
Tissue 
Lung Pleura Peritoneum Pericardium Joint CNS 
S. suis P1 8/10 2/10 1/10 2/10 2/10 2/8 6/10 
S. suis P20 7/10 1/10 3/10 mo 0/10 0/8 7/10 
There were no significant differences between the groups. 
O) (O 
-Aerosolized S. suis, n=6 
-NH3 pretreatment + aerosolized S. suis, n=6 
•NH3 pretreatment Intranasal S. suis, n=6 
Day 0 Day 1 Day 2 Day 3 Day 4 Days Day6 Day? Day8 Day9 Day 10 Day 11 Day 12 Day 13 Day 14 
Day post S. suis challenge 
Figure 1. Cumulative mortality of animals in each treatment group per day of experiment 1. 
10 
Vaccinated, NHS pretreatment + intranasal S. suis, n=9 9 
unvaccinated, NH3 pretreatment + intranasal S. suis, n=10 8 
Unvaccinated, Intranasal S. suis, n=10 
7 
-^Control, n=10 
6 
5 
4 
3 
2 ^ 
1 
0 
Day 14 Day IS Day 16 Day 17 Day 18 Day 19 Day 20 Day 21 Day 22 Day 23 Day 24 Day 25 Day 26 Day 27 Day 28 
Day of study 
Figure 2. Cumulative mortality of animals in each treatment group per day of experiment 2 following S. suis 
inoculation on Day 14. 
S. suis P1, n=10 
S. suis P20, n=10 
•>< INJ 
Day 0 Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 Day 9 
Day Post S. suis Challenge 
Figure 3. Cumulative mortality of animals in each treatment group per day of experiment 3. 
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CHAPTER 4. CHARACTERIZATION OF A NEUTROPHIL SUPPRESSIVE 
FACTOR FROM STREPTOCOCCUS SUIS 
A paper to be submttted for publication 
Gayle B. Brown and James A. Roth 
Abstract 
Streptococcus suis (S. suis) commonly colonizes the tonsils of healthy pigs. 
However, it is capable of invading and causing septicemia, meningitis, arthritis, 
serositis and/or pneumonia. Some potential virulence factors of S. suis have been 
identified but their roles in evasion of immune destruction and induction of disease 
are not understood. The objective of this study was to begin to identify factors that 
inhibit neutrophil function and that may be important in the pathogenesis of S. suis-
induced disease. S. suis, serotype 2, isolated from the meninges of a pig showing 
signs of meningitis was inoculated into Todd-Hewitt broth and grown for 18 hours at 
37°C in 5% CO2 air. The bacteria were then pelleted, washed twice with PBS and 
resuspended in 2 ml of PBS. The resuspended bacteria were incubated for two 
hours at 37° 0 in 5% CO2 air. The bacteria were pelleted and the supernatant 
collected and filtered through a 0.2 micron filter. Porcine neutrophil iodination, 
cytochrome C reduction. Staphylococcus aureus ingestion, and random migration 
under agarose assays were performed with supematant added to the assays at 10% 
of the final volume and PBS as a control. S. suis supematant suppressed the 
iodination reaction to 49% of control, the other three neutrophil function assays were 
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not altered, or were only mildly suppressed. The suppressive activity detected by 
the iodination assay was heat stable, was not present in a capsular preparation and 
was not present in supematant prepared by incubating S. suis at 4°C instead of 
37°C. When the supematant was passed through a 1000 dalton cut-off membrane 
filter the filtrate suppressed the iodination reaction to 61% of the PBS control. The 
1000 dalton filtrate was fractionated using reverse phase-high performance liquid 
chromatography and the suppressive activity was found in one of the fractions 
collected. The suppressive fraction contained guanine and at least two other 
unknown components that may be other bases and/or nucleosides. The exact 
molecular structure, mechanism of action and contribution to S. suis virulence of the 
neutrophil suppressive factor remains to be determined. 
Introduction 
Streptococcus suis (S. suis) is an alpha-hemolytic gram positive organism 
that can induce disease in pigs, humans, cattle, dogs and other animals.^® S. suis-
induced disease is predominately a problem in young pigs, especially nursery age, 
but it can cause disease in any age pig. Meningitis, arthritis, septicemia and/or 
pneumonia characterize the disease.^® 
S. suis colonizes the tonsils of healthy pigs.® The proposed pathogenesis of 
the disease is that monocytes phagocytose virulent S. suis organisms from the 
tonsils. The organisms survive and replicate in the monocyte, and are distributed 
systemically by the monocytes. Once spread systemically they are released from 
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their intracellular location, evade ingestion and killing by the polynriorphonuclear cells 
(PMNs) and induce clinical disease.^ 
Potential virulence factors described for S. suis include capsule, suiiysin (a 
hemolysin), albumin-binding protein, immunoglobulin-binding protein, muramidase 
released protein, extracellular factor, hemagglutinins, and an adhesin.'*-^ ""^®*^®'^  
The capsule is the only factor that has been found to be critical for virulence.'^  The 
role of the capsule in virulence is thought to be inhibition of phagocytosis and 
possibly increased survival in phagocytes.^ Capsular thickness shows some 
correlation to resistance to PMN killing.However, resistance to PMN killing was 
observed in an isolate that did not have a thick capsule suggesting that other factors 
are involved in resistance to PMN killing. 
The interaction of S. suis with PMNs is clearly important in the pathogenesis 
of the disease. PMNs are part of the eariy defense against S. suis infection. Many 
virulence factors of bacteria are capable of inhibiting PMN function. The objective of 
this research was to begin to characterize and identify virulence factors of S. suis 
that interfere with phagocyte killing. Instead of comparing differences between 
virulent and avirulent isolates of S. suis in order to discover virulence factors, a 
virulent isolate was used and its effect on PMN function was monitored. A neutrophil 
suppressive molecule was identified and found to be a small molecule that 
decreases the myeloperoxidase (MP0)-H202-halide bactericidal mechanism of 
porcine neutrophils. 
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Materials and Methods 
S. suis serotype 2 isolate 
The bacteria used for this research was S. suis serotype 2 isolate ISU-VDL 
#40634/94 described previously.^ Briefly, the isolate was first cultured by the Iowa 
State University Veterinary Diagnostic Laboratory (ISU-VDL) from the meninges of a 
ffeid case of a pig showing signs of meningitis. The isolate was inoculated 
intravenously into another pig. When the pig showed signs of meningitis the 
brain/meninges were harvested and homogenized. The brain/meninges 
homogenate is stored frozen at -80°C. 
S. suis supernatant 
S. suis serotype 2 (1.4 x 10^ cfu) in the brain/meninges homogenate was 
inoculated into 40 ml of Todd-Hewitt Broth (THB) (Difco) and incubated for 18 hours 
at 37®C in 5% CO2 air. The bacteria were then pelleted, washed twice in phosphate 
buffered saline (PBS) and then resuspended in two ml of PBS. The resuspended 
bacteria were incubated for two hours at 37°C in 5% CO2 air. The bacteria were 
then pelleted and the supematant collected and filtered through a 0.2 micron filter. 
Heat stability of the supematant was determined by heating the supematant 
to 121°C for 15 minutes. To detemnine If capsule was responsible for the 
suppression of the iodination reaction, a supematant was prepared as described 
above with minor modifications. After washing with PBS, the pellet was 
resuspended in PBS, then boiled for 15 minutes to allow the release of capsular 
material into the supematant. The cells were pelleted and the supematant collected 
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and filtered as described above. To determine whether the S. suis needed to be at 
physiologic temperature in order to release the suppressive factor extracellularly, the 
supernatant was prepared as described above except that instead of a two hour 
incubation at 37°C the S. suis in PBS was Incubated at 4°C. 
Fractionation using molecular weight filters 
The 0.2 micron filtered supematant was passed through a 10,000 dalton cut­
off membrane by centrifugation (Amicon CP10, Amicon, Beverly, MA). The filtrate 
that passed through the 10,000 dalton cut-off membrane was tested and found to 
contain the neutrophil suppressive activity. Using a stirred cell system, this filtrate 
was then passed through a 1000 dalton cut-off membrane (Millipore, Bedford, MA) 
and the filtrate collected (1000 dalton filtrate). This filtrate was checked for 
suppressive activity on porcine PMNs and the remainder was stored at -80°C. 
Reverse phase-high performance liquid chromatography 
The 1000 dalton filtrate was separated (100 {xl aliquots) on a CIS column 
(Jupiter 300, 5 um particle size, 4.6 X 250 mm, Phenomenex, Torrance, CA) using a 
Beckman 12114M pump and a 406 Analog Interface Module (Beckman Instruments, 
Inc., Palo Alto, CA). One half minute timed fractions over 30 minutes were collected 
with a gradient of acetonitrile (0-30%) in 0.1% trifluoroacetic acid with a flow rate of 
0.5 ml/min. Fractions were collected (SC100 fi^ action collector, Beckman 
Instruments, Inc., Palo Alto, CA) and pooled with similar fractions of previous runs, 
evaporated to dryness under vacuum, dissolved in PBS and tested for activity, or 
analyzed for composition. 
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Amino acid analysis 
Amino acid analysis was perfomfied by the ISU Protein facility using a Perkin 
Elmer Applied Biosystems Model 420 Derivatizer/Analyzer Amino Acid Analysis 
System (Foster City, CA). Samples were hydrolyzed at 150°C with 6N HCL using a 
PicoTag workstation (Waters), derivatized with phenylisothiocyanate (PITC) and 
separated on a C18 silica column. The derivatized amino acids were detected at 
254 nm. 
Amino acid sequence determination 
A 492 Procise Protein Sequencer (Perkin Elmer Applied Biosystems, Inc. 
Foster, CA) was used to attempt to determine an amino acid sequence. This 
sequencer uses the Edman degradation method of sequencing. 
Molecular weight determinations 
Determination of the molecular weight was attempted using matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI) (Finnigan MAT 
Lasermat 2000, Hemel Hempsted, England). The sample was loaded onto a sample 
spot with matrix and ionized with pulsed nitrogen laser at 337 nm. 
PMN isolation 
Porcine neutrophils were isolated from whole blood that was collected into 
acid-citrate-dextrose anticoagulant. The anticoagulated blood was centrifuged for 20 
minutes at 700 x g. The plasma was discarded and the red blood cells were lysed 
by flash lysis with cold phosphate buffered deionized water; isotonicity was restored 
by adding 2.7% sodium chloride. The remaining cells were resuspended in Hanks 
buffered saline solution without Ca++, Mg++ or phenol red (HBSS) (GibcoBRL, 
79 
Grand Island, NY) and layered over HIstopaque 1.077 (Sigma, St. Louis, MO). After 
centrrfugation at 525 x g for 30 minutes the polymorphonuclear cells (PMNs) were 
found in the pellet with the remaining red blood cells. The remaining red blood cells 
were lysed as described above. The PMNs were washed with HBSS and then 
resuspended in HBSS to a concentration of 5.0 x 10^ PMN per ml for use in the 
neutrophil function assays. 
Neutrophil function assays 
The assays used were iodination, cytochrome C reduction, Staphylococcus 
aureus ingestion and random migration under agarose. These assays were 
performed as previously described.®'^ ®'^ ® The effect of the S. suis supematant on 
these assays was evaluated by comparing to a PBS control and calculating the 
percent of PBS control. 
The iodination assay evaluates the influence of S. suis virulence factors on 
the activity of the myeloperoxidase-hydrogen peroxide-halide (MPO-HaOa-halide) 
antibacterial system of the neutrophil. The standard reaction mixture for the 
detemriination of stimulated iodination contained 2.5 x 10® PMNs, 0.05 nCi ^^®l. 20 
nmole Nal, 0.5 mg of opsonized zymosan, 50.0 (il of either S. suis supematant or 
PBS and 325 |j.l of Earle's balanced salts solution. The reaction mixture was 
incubated 20 minutes at 37°C, and the reaction was stopped by addition of 3.0 ml of 
cold 10% trichloroacetic acid. The resulting precipitate was washed with cold 
trichloroacetic acid and the amount of radioactivity in the precipitate detennined in a 
gamma counter. The incorporation of Nal was expressed as nmole of Nal/10^ 
PMNs/hr. The assay was perfomned in duplicate. 
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The cytochrome C reduction assay was used to evaluate the Influence of the 
potential S. suis virulence ^ctor on the production of superoxide anion during the 
burst of oxidative metabolism by the neutrophil. The standard reaction mixture for 
the determination of the influence of S. suis supernatant on this function contained 
2.5 X 10^ PMNs, 0.5 mg of opsonized zymosan as a stimulant, and 30 l^ of either S. 
suis supernatant or PBS in 300 iil of a 0.32 mM solution of cytochrome C in HBSS. 
The assay was perfomned in duplicate in microtiter plates. The reaction was allowed 
to proceed for 5 minutes at 37°C. The optical density (OD) was determined by the 
difference of the OD at 550 nm and 650 nm using a micro-ELISA plate reader. 
The S. aureus ingestion assay was used to evaluate the influence of S. suis 
supernatant on the ability of porcine neutrophils to Ingest bacteria. The standard 
reaction mixture contained 100 nl of ^^®l-labeled heat-killed S. aureus, 50 ^1 of 
neutrophils (2.5 x 10^), (bacteria to PMN ratio = 60:1), 50 |il of a 1:4 dilution of anti-
S. aureus serum, 300 ^1 of Earie's BSS, and 50 |il of either S. suis supernatant or 
PBS as a control. The reaction was incubated at 37°C for 10 minutes, after which 
the non-phagocytlzed S. aureus was removed by adding 0.5 units of lysostaphin 
(Sigma) to each tube. The PMNs were washed twice and the amount of PMN-
associated radioactivity was detemiined. The percentage of ^^ l^-labeled S. aureus 
ingested was calculated. The assay was performed in duplicate. 
Migration under agarose was evaluated by adding 10 nl of S. suis, or PBS as 
a control, to 90 ^1 of the standard PMN suspension, then 10 |il of that mixture was 
added to wells cut in agarose (bicarbonate-buffered Medium 199 with Earie's salts 
containing 0.8% antibiotic). The agarose plates were incubated 18 hours in a 
humidified incubator containing 5% COaair. Following incubation, the cells were fixed 
with glutaraldehyde, stained with crystal violet, and the area of PMN migration (in 
mm^) away from the wells was measured. The assay was performed in duplicate. 
Results 
Characterization of S. suis supernatant 
Unfractionated S. suis supernatant suppressed iodination activity of porcine 
PMNs to 48.7% of the PBS control value. The cytochrome C reduction, S. aureus 
ingestion and migration under agarose activities were not affected, or were only 
mildly affected (Table 1). Since the iodination assay was significantly suppressed, 
this assay was used to monitor for the presence of neutrophil suppressive activity. 
Suppression of the iodination reaction by S. suis metabolic supematant after heating 
at 121®C for 15 minutes was unchanged (50.0 % of PBS control + 6.5, SEM). 
Preparing the supematant using a 4°C incubation temperature for 2 hours, instead of 
37°C, resulted in supematant that did not suppress the iodination reaction (100.6% 
of PBS control + 8.5, SEM). The supematant prepared by boiling the S. suis cells 
was only mildly suppressive to PMN iodination activity (86.7% of PBS control + 2.7 
SEM). Colony counts before and after the 2 hour 37°C incubation in PBS were not 
significantly different, indicating there was no cell death causing the release of 
suppressive factors. 
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Fractionation of S. suis metabolic supernatant 
The 10,000 dalton filtrate had similar suppressive activity as the 
unfractionated supematant and the 1000 dalton filtrate also had suppressive activity 
similar to the unfractionated metabolic supematant (45.6% + 3.1 and 61.3% + 4.2, 
respectively) 
The 1000 dalton filtrate was fractionated using RP-HPLC (Figure 1). The 
firactions containing major peaks were checked for their ability to suppress neutrophil 
iodination reaction (Table 2). Fraction 32 suppressed neutrophil iodination reaction 
similar to the unfractionated metabolic supematant and was further evaluated for 
composition. 
Determination of the composition effraction 32 
Amino acid analysis results were inconclusive and attempts to determine the 
amino acid sequence effraction 32 were not successful. However, during the amino 
acid analysis, a large peak that did not correlate with any of the amino acid 
standards was identified in the C-18 RP-HPLC separation of the hydrolyzed and 
derivatized sample. In order to detennine the composition of this peak, a hydrolyzed 
sample effraction 32 sample was injected Into a reversed-phase CI 8 column and 
the sample eluted with a gradient of acetonitrile in 0.1% trifluroacetic acid (0-100%) 
over 50 minutes at 200 |al per minute. The chromatogram revealed three peaks and 
is shown in Figure 2. When a guanine standard was injected into and eluted from 
the 018 column in the same manner as hydrolyzed fraction 32, the guanine had a 
similar elution time as peak 2 (Figure 2). MALDI mass spectrometry was done on 
each of the three peaks shown in Figure 2. Peak 2 had a MALDI signal at m/z = 
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152; the guanine standard also produced a MALOl signal at m/z == 152. Peaks 1 and 
3 have not been positively identified but MALDI results suggests that Peak 3 may be 
a form of guanine. At low laser energies it has a MALDI signal at m/z = 225 and at 
higher laser energies that may cause breakdown of the molecule, there is a signal at 
m/z =152 where the guanine standard gives a signal. Peak 1 has a MALDI signal at 
m/z =112. This would be where cytosine would be expected to produce a signal, so 
it is possible that peak 1 contains cytosine. 
The MALDI of the unhydrolyzed fraction 32 was inconclusive. The molecular 
weight of the entire unhydrolyzed fraction remains unknown. 
Discussion 
Metabolically active S. suis releases a factor into the supernatant that passes 
through a 1000 dalton cut-off membrane filter and suppresses porcine neutrophil 
MPO-HaOa-halide antibacterial activity but not neutrophil oxidative burst, ingestion or 
migration under agarose. It Is heat stable and Is not present in a capsular 
preparation. The S. suis must be metabolically active to release the neutrophil 
suppressive factor Into the supernatant. The suppressive factor appears to be 
composed of guanine and at least two other components that may be other bases 
and/or nucleosides. 
Neutrophils are important in host protection against extracellular bacterial 
infections and are important in host defense against S. suis. Under certain 
circumstances, S. suis invades the host and evades immune destruction by 
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neutrophils resulting in disease. The objective of this study was to determine if S. 
suis secretes products extracellularly that inhibit innportant bactericidal activities of 
neutrophils. Important functions of neutrophils include migration to the site of 
infection, phagocytosis, oxidative burst and production of oxygen radicals, 
degranulation and release of enzymes and cationic peptides, and the MPO-H2O2-
halide system. Myeloperoxidase is released by the granules and catalyzes the 
reaction of H2O2 and halides resulting in the production of hypohalides. These 
hypohalides oxidize bacterial proteins. 
The assays used in this study indirectly measure the neutrophil migration, 
phagocytosis, oxidative burst, and the MPO-HaOa-halide system by measuring 
migration under agarose, S. aureus ingestion, cytochrome C reduction and 
iodination of proteins, respectively. The porcine neutrophil suppressive factor only 
suppressed the MPO-HzOa-halide system. Since the oxidative burst was not 
affected, it Is likely that the production of H2O2 was not affected. Therefore, the 
suppressive factor may be affecting the degranulation of myeloperoxidase or its 
catalytic activity. 
Virulent S. suis is able to survive in phagocytic cells. It is possible that the 
suppressive factor identified here contributes to the survival of the S. suis within the 
phagocytes by decreasing degranulation into phagosomes. 
Purines and nucleosides are known to affect neutrophil function. Guanine, 
guanine monophosphate and adenine released by Brucella abortus and 
Haemophilus somnus are known to suppress bovine PMN iodination activity.^ ® 
These are facultative intracellular bacteria and it is proposed that the release of the 
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purines and nucleosides allow the bacteria to evade destnjction in the neutrophil. 
The bovine neutrophil suppressive factor was found in the metabolic supernatant of 
H. somnus similar to S. suis. For B. abortus the purines and nucleosides were not 
released into the supernatant until the bacteria were heated. 
Receptors for adenosine are found on human neutrophils.® The binding of 
adenosine to the A2 adenosine receptor of human neutrophils results in decreased 
oxidative burst, degranulation and decreased binding of activated neutrophils to 
endothelial cells because of decreased up-regulation of beta 2 integrins and 
decreased loss of L-selectins on the neutrophil surface.® Guanosine is a purine like 
adenosine: however, it does not seem to affect human neutrophils in the same 
manner as adenosine. It is not known if human neutrophils have receptors for 
guanosine. It is possible that bovine and pig neutrophils have receptors for 
guanosine and that binding of this receptor results in the decreased 
myeloperoxidase-HaOa-halide reaction. It is not known whether porcine and bovine 
neutrophils have adenosine receptors. Possibly these species have a receptor that 
will bind either of the purine nucleosides. It would be interesting to evaluate the 
effect of adenosine receptor antagonists on porcine neutrophils to determine if the 
presence of the antagonist would alter the effect of the S. suis suppressive factor. 
The results presented here suggest that S. suis releases a molecule 
composed of purines and other bases and/or nucleosides that inhibits neutrophil 
function. The exact nature of this molecule, its mechanism of action and its 
contribution to S. suis virulence remains to be determined. A clear understanding of 
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the molecule and how It functions may help in better understanding the 
pathogenesis of S. suis. 
In order to determine the exact structure of this molecule several things must 
be done. A large quantity of purified sample must be prepared so that reliable 
repeatable testing can be done. Determination of which purines, pyrimidines, 
nucleotides and nucleosides are present can be done by comparing elution times 
through the C18 column of the hydrolyzed unknown flections to prepared standards. 
MALDI can be used to confirm mass of the unknowns and compared to MALDI 
results of the standards. The purified suppressive factor should be analyzed for 
carbohydrate, e.g., ribose or deoxyribose and nucleotide sequencing should also be 
done. The results of amino acid analysis have been confusing due to interference 
by the guanine in the procedure. An elemental analysis of the carbon to nitrogen 
ratio would help to clarify the presence or absence of amino acids. These 
procedures should provide much needed information regarding the complete 
composition of this molecule. 
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Table 1. Effect of unfiractionated S. suis metabolic supernatant on porcine PMN 
function, expressed as a mean (+ SEM) percent of the value for the PBS control. 
Percent of PBS control 
n = 3 
lodination 48.7 ±1.1 
Cytochrome C reduction 91.7 + 7.1 
S. aureus ingestion 95.0 + 4.7 
Migration under agarose 111.7 + 7.6 
Table 2. Effect of RP-HPLC fractions shown in Figure 1 on iodination activity of 
porcine PMNs. Expressed as a mean (+ SEM) percent of the value for the PBS 
control. 
RP-HPLC fractions of the 1000 da filtrate Percent of PBS control 
n = 3 
Fraction 24 88.3 + 2.3 
Fraction 25 89.0 + 3.5 
Fraction 29 91.7 + 5.7 
Fraction 32 53.0 + 1.5 
Fraction 34 89.7 + 6.4 
Fraction 40 94.0 + 10.0 
Fraction 41 97.7 + 5.0 
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CHAPTER 5. GENERAL CONCLUSIONS 
Summary of Results 
The studies presented in this dissertation address two aspects of the 
pathogenesis of S. suis disease. The first aspect is experimental reproduction of the 
clinical disease and lesions, and the second aspect is the interaction of S. suis and 
neutrophils. The two are related in that in order to cause clinical disease and lesions 
the S. suis must evade destruction by neutrophils. 
Previously published S. suis challenge models used intravenous Inoculation 
of pigs®, intranasal inoculation of S. suis to pigs infected with another pathogen^ '* ®, 
and intraperitoneal inoculation of mice as a model for pigs.^ In order to evaluate 
potential virulence factors, vaccine candidates and treatment regimes, an intranasal 
challenge model without co-infection is desirable. The objective of the experiments 
in the first part of this dissertation was to develop a S. suis challenge model that 
mimicked route of exposure, clinical syndrome, and lesions induced in the natural 
disease. Reports indicated that S. suis administered experimentally via the 
intranasal route to healthy pigs would not consistently produce disease.^ '* It was 
hypothesized that several factors may be required to have a successful intranasal 
experimental challenge model. These factors included: irritation of the nasal 
mucosa prior to exposure to S. suis, aerosolization of the bacteria instead of 
intranasal inoculation, a high inoculum titer, a challenge bacteria that was directly 
firom an infected pig brain with as little in vitro passaging as possible, and 
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administration of the challenge inoculum in the growth media because it may contain 
important virulence factors. 
A set of three experiments was performed to develop the intranasal S. suis 
challenge model. All three experiments used a S. suis serotype 2 isolate that was 
obtained by aseptically harvesting the brain/meninges of a pig showing signs of 
central nervous system disease. The first experiment examined aerosolized S. suis 
with or without pre-exposure to the nasal irritant (ammonia) and also compared the 
disease induced by aerosolized S. suis and intranasally inoculated S. suis in pigs 
exposed to aerosolized ammonia. In this experiment at least 80% of the pigs in 
each group had some sign of infection. However, only 50% of the pigs that received 
aerosolized S. suis had the bacteria isolated from an internal tissue. There was no 
difference between the pigs that received the aerosolized S. suis following exposure 
to ammonia and the pigs that were exposed to aerosolized S. suis only. Therefore, 
the disease induced by aerosolized S. suis was not enhanced by pre-exposure to 
ammonia indicating that nasal mucosal Irritation was not required. There was a 
difference in the disease induced between the pigs that were exposed to the 
ammonia and then challenged with aerosolized S. suis and the pigs that were 
exposed to ammonia and then challenged with S. suis by intranasal inoculation. 
More of the pigs that were exposed by intranasal inoculation had clinical disease, 
the disease was more severe (higher mortality) and S. suis was isolated from more 
tissues. The role of exposure to ammonia in these groups was not evaluated. 
A second experiment was designed to evaluate the role of the ammonia when 
the S. suis was administered by intranasal inoculation. The results of this 
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experiment indicated that the number of pigs showing clinical disease, the bacterial 
isolation, and mortality following exposure to S. suis by intranasal inoculation was 
not influenced by pre-exposure to ammonia. The only difference between the two 
groups was that the pigs pre-exposed to the ammonia had a more rapid onset of the 
disease. 
The intranasal challenge model was used successfully to evaluate the 
avirulent S. porcinus vaccine as a candidate for protection against S. st//s-induced 
disease. The vaccine reduced the incidence of mortality, recovery of S. suis and 
clinical signs after S. suis challenge; however, the differences were not statistically 
significant. Therefore, further development of the S. porcinus vaccine was not 
pursued. 
The third experiment was designed to begin to determine why the challenge 
model was successful. The objective of the experiment was to determine if the 
intranasal challenge induced disease because the stock culture was a 
brain/meninges homogenate and the challenge Inoculum was prepared without 
further passaging. The stock culture was passaged 20 times on blood agar plates 
(P20) and then a challenge inoculum was prepared in the same manner as the 
original challenge inoculum (P1). Both P1 and P20 caused signs of clinical disease 
in > 80% of the pigs. S. suis was isolated from internal tissues of 80% (P1) and 70% 
(P20) of the pigs, and there was 40% mortality in the P1 group and 60% mortality in 
the P20 group. There was no significant difference (p>0.05) between these two 
groups for the parameters measured. Therefore, in vitro passaging 20 times did not 
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decrease the virulence of the bacteria. This experiment confirmed the reproducibility 
of this model. 
The reason the S. suis challenge model described in this dissertation is 
successful in mimicking the natural disease is still unclear. One possibility is that the 
bacteria are administered in the growth media. The growth media may contain 
Important virulence factors that allow tiie bacteria to evade immune destruction and 
establish infection that causes clinical disease. 
The second part of this dissertation partially addresses the hypothesis that 
the growth media contains important virulence factors. The S. suis serotype 2 
Isolate was grown in vitro in Todd Hewitt Broth and then washed and incubated in 
phosphate buffered saline (PBS) for 2 hours. The supernatant was examined for its 
influence on porcine neutrophil function. The supematant suppressed the 
myeloperioxidase-H202-halide activity of neutrophils to 49% of a PBS control, it did 
not suppress or only mildly suppressed neutrophil migration under agarose, 
ingestion of Staphylococcus aureus or oxidative metabolism when compared to PBS 
control. The suppressive activity in the supematant was monitored using the 
iodination assay that measures the MPO-HaOa-halide activity of neutrophils. The 
suppressive activity in the supematant was stable to heating, was not present if the 
supematant was prepared at 4°C instead of 37°C and was not present in a S. suis 
capsular preparation. The suppressive activity passed through a 1000 dalton cut-off 
filter. The filtrate was then fractionated by C-18 reverse phase-high performance 
liquid chromatography (RP-HPLC) and tiie suppressive activity was recovered from 
fraction 32. Fraction 32 was then evaluated for composition and found to contain 
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guanine and two unknown components that may be other bases and/or nucleosides. 
Therefore, S. suis releases a small molecular weight molecule that decreases 
neutrophil function which may contribute to the virulence of S. suis. 
Application to the Problem 
The challenge model developed is an important tool for furthering the 
understanding of S. suis pathogenesis. This model is important for the evaluation of 
potential virulence factors, vaccine candidates and treatment regimes. It is unique 
from other S. suis challenge models that have been reported in that the S. suis is 
administered via the natural route of infection, it is the only pathogen administered 
and the clinical disease and lesions produced are similar to those that are observed 
in the field. This challenge model has been used in two studies evaluating various 
prevention and therapeutic strategies for S. suis. Manuscripts reporting the results 
of these studies are in preparation. 
The interaction between neutrophils and S. suis is important. It is thought that 
virulent isolates of S. suis are able to survive in phagocytic cells and avirulent 
isolates are not able to sun/ive.^-^ The mechanism that allows the streptococcus to 
do this is unknown. Capsule thickness shows some correlation to increased 
resistance to neutrophil killing; however, the resistance to neutrophil killing was not 
always correlated with a thickened capsule.® Therefore, there are other factors that 
may allow the virulent isolates to survive and resist phagocytic killing. The research 
presented In this dissertation describes a molecule that is released by S. suis into 
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saline that decreases the neutrophil MPO-HzOa-halide activity. This factor may be 
important in the virulence of S. suis and in its interaction with neutrophils in vivo. 
Recommendations for Future Research 
Further research is needed to fully characterize the challenge model. 
Understanding why this model successfijlly reproduces the disease may provide 
information about the pathogenesis of S. suis. Some possible reasons why the 
challenge model worked include: the high titer of the challenge inoculum, 
administration of the S. suis in growth media without washing, the way the inoculum 
was grown, unique attributes of the isolate, or age of the pigs challenged. A 
variation of this model was used in a porcine respiratory and reproductive virus and 
S. suis coinfection model. We diluted the standard S. suis challenge inoculum 1:10 
in a balanced salt solution, this not only decreased the titer but also diluted the 
growth media. The diluted inocula only caused clinical signs and mortality in 14% of 
the animals. This indicates that the titer and/or administration in undiluted growth 
media are important for this challenge model to induce disease. It would be 
interesting to test other S. suis isolates that were originally recovered from cases of 
meningitis, and under different challenge conditions did not induce disease, using 
identical procedures to those reported here. 
A better understanding of the interaction of S. suis and neutrophils is needed 
to develop better preventive and therapeutic regimes. Identification of the exact 
structure and mechanism of action of the neutrophil suppressive factor described in 
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this dissertation would help in understanding that interaction. In addition, 
determining the role this molecule plays in vivo would also be important in 
understanding its significance in the pathogenesis of S. suis. 
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